



Universiteit
Leiden
The Netherlands

Affinity-based profiling of the adenosine receptors

Beerkens, B.L.H.

Citation

Beerkens, B. L. H. (2023, November 9). *Affinity-based profiling of the adenosine receptors*. Retrieved from <https://hdl.handle.net/1887/3656497>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3656497>

Note: To cite this publication please use the final published version (if applicable).

Chapter 4

A Chemical Biological Approach to Study G Protein-Coupled Receptors: Labeling the Adenosine A₁ Receptor using an Electrophilic Covalent Probe

Bert L. H. Beerkens, Çağla Koç, Rongfang Liu, Bogdan I. Florea, Sylvia E. Le Dévédec, Laura H. Heitman, Adriaan P. IJzerman, and Daan van der Es

Abstract

G Protein-Coupled Receptors (GPCRs) have been known for decades as attractive drug targets. This has led to the development and approval of many ligands targeting GPCRs. Although ligand binding effects have been studied thoroughly for many GPCRs, there are multiple aspects of GPCR signaling that remain poorly understood. The reasons for this are the difficulties that are encountered upon studying GPCRs, e.g. a poor solubility and low expression levels. In this work, we have managed to overcome some of these issues by developing an affinity-based probe for a prototypic GPCR, the Adenosine A₁ Receptor (A₁AR). Here we show the design, synthesis and biological evaluation of this probe in various biochemical assays, such as SDS-PAGE, confocal microscopy and chemical proteomics.

ACS Chem Biol **2022**, 17, 3131–3139.

Introduction

The adenosine receptors (A_1 , A_{2A} , A_{2B} and A_3) are class A G Protein-coupled receptors (GPCRs) that respond to extracellular levels of adenosine.^[1,2] These receptors play a role in a wide variety of physiological and pathological processes, ranging from the suppression of immune responses to the regulation of nociception.^[3,4] This versatile role has prompted decades of research towards the effects of modulating adenosine receptors and led to the development of multiple clinical candidates. However only few chemical entities have thus far reached the markets.^[5,6]

One reason for the lack of success might be the multitasking role of the adenosine receptors throughout the human body, e.g. the adenosine A_1 receptor (A_1 AR) influences lipolysis in adipocytes, reduces ischemic injury in cardiomyocytes and shows analgesic activity in the spinal cord.^[4,7,8] Other reasons might be receptor oligomerization, biased downstream signaling and the presence/absence of post-translational modifications (PTMs).^[9,10]

The latter observations are not limited to the adenosine receptors, but have been found to play a role in the signaling of GPCRs in general.^[11,12] Altogether, there is a plethora of possible mechanisms that could affect targeting of GPCRs in a specific disease state. As GPCRs are the target of roughly one third of the FDA approved drugs (~34% in 2017)^[13], it is important to get a better picture of all possible aspects that have an influence on receptor signaling.

Parallel to the development of novel assays and more accurate read-outs in existing assay setups, the development of tool compounds is a valid approach to obtain a better understanding of GPCRs.^[14,15] To this end, our group recently developed LUF7746: a partial agonist for the A_1 AR equipped with an electrophilic fluorosulfonyl group, which facilitated covalent binding to the A_1 AR (Figure 1A).^[16] Covalent ligands for GPCRs have especially proven useful in structural studies, 'locking' multiple individual receptors into the same conformation.^[17,18]

Aside from covalent ligands, multiple functional ligands have been developed over the years to expand the scope of GPCR profiling.^[15] Among these tool molecules are ligands that are conjugated to e.g. fluorophores, bio-orthogonal click handles and photo-activatable groups.^[19–22] In other protein families such as hydrolases and proteases, many so-called activity-based probes have already been developed to broadly characterize the respective protein family.^[23,24] Having such an extensive arsenal of probes for GPCRs would allow for a more thorough investigation of these important drug targets in biological systems.

Activity-based probes consist of three parts: a selective targeting moiety, a reactive electrophilic group (warhead), and a reporter tag to detect the probe-bound proteins.^[25] Classical activity-based probes target the active site of an enzyme, using warheads that make use of the enzyme's intrinsic mechanism to react.^[23,24] GPCRs on the other hand, do not have such an active site pocket. Therefore, in case of GPCRs, affinity-based probes (AfBPs) have been developed that either use photoactivatable or highly electrophilic groups as warhead.^[26–31] AfBPs thus rely on high affinity and selectivity towards a protein target for selective labeling. Besides that, there are various challenges associated with the biochemical profiling of GPCRs. First, most receptors have low expression levels, even when stably overexpressed in model cell lines.^[32–34] Second, as mentioned before, oligomerization and PTMs greatly influence the behavior and appearance of GPCRs.^[35,36] Third, GPCRs are membrane proteins, which are poorly soluble in aqueous media and thus prone to solubility issues.^[37–39]

Recently, a handful of AfBPs has been developed to target and label the adenosine receptors. Among these are a clickable antagonist for the A_{2A} AR and a clickable antagonist with high

affinity for both the A₁AR and A₃AR.^[29,31] The application of these probes however, has been limited to gel-based experiments. Presumably the aforementioned issues, such as expression levels and presence of PTMs, have impeded the detection of adenosine receptors in a biochemical setup. Therefore, further exploration on the design, synthesis and applicability of such probes is warranted.

In this study, we explored another avenue to study the adenosine receptors with AfBPs, enabling the profiling of the A₁AR in a multitude of biochemical assays. To achieve this, we developed the first agonistic AfBP for the A₁AR, starting from the aforementioned covalent partial agonist LUF7746. LUF7746 already contains two elements of an AfBP, the only element lacking is the reporter tag for detection.^[16] An alkyne group was chosen as ligation handle to be conjugated to a reporter tag in the Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC).^[40,41] The choice of the alkyne moiety has two advantages compared to a direct conjugation with a reporter group (one-step-probe). First, the alkyne group is a small moiety and thus accounts for minimal steric clashes in the binding pocket of the A₁AR. Secondly, having such a ligation handle provides the flexibility to 'click' various types of reporter tags onto the probe-bound protein.

In an exemplary GPCR profiling assay, live cells or membrane fractions are first incubated with the probe to selectively label the desired receptor in the presence of other proteins (Figure 1B). In the subsequent incubation step, the desired reporter group is 'clicked' onto the probe, effectively labeling the receptor. Lastly, the reporter-bound receptor is further processed, depending on the type of detection method. In our case, three different techniques were used to detect the A₁AR: SDS-PAGE, chemical proteomics and confocal microscopy. Here, we show our synthesized probe, LUF7909, was successfully used in all three of these profiling setups. Taken together, this allows us to gain more insight into various receptor properties, such as expression, glycosylation and the effects of ligand binding.





Figure 1. (A) A₁AR-targeting 3,5-dicyanopyridines: covalent partial agonist LUF7746 and AfBP LUF7909. (B) Typical affinity-based protein profiling workflow used in this study. First, membrane fractions or live cells are incubated with alkyne-containing AfBP. Second, the alkyne moiety of the probe is conjugated to an azide-containing reporter group through the Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC). Third, the probe-bound proteins are being processed for further detection methods. These include SDS-PAGE experiments, chemical proteomics and confocal microscopy. Figure partly created with BioRender.com.

Results and Discussion

Design and Synthesis of A₁AR-targeting AfBPs

As mentioned before, our AfBP-design includes an alkyne moiety. In order to explore the effects that introducing an alkyne has on the binding of LUF7746 to the receptor, multiple ligands were synthesized (i.e. **1**, **2**, **3** and **4**) each having the alkyne group substituted at a different position of the scaffold (Scheme 1). In all four cases, the synthesis started from the respective benzaldehydes (**6a-c**) which were converted to the corresponding 3,5-dicyanopyridines (**7a-c**) through a multiple component reaction using malononitrile and thiophenol.^[42] 3,5-Dicyanopyridine **7c** was subjected to a Sandmeyer reaction (to furnish chloride **8**), followed by a substitution by propargyl amine (to give alkyne **9**).^[8] The four 3,5-dicyanopyridines (**7a-c** and **9**) were deprotected using thioacetate, (**10**, **11a-c**) and subsequently used in a nucleophilic substitution reaction with compound **20** to yield the AfBPs **1**, **2**, and **3**.

In case of probe **4**, the alkyne group was introduced onto the warhead-containing linker moiety prior to nucleophilic attack of the thiol. In brief, 3-bromopropanol was protected with a TBDMS group (**13**) and converted to compound **14** by a dropwise addition of propargyl amine. 4-Fluorsulfonyl benzoic acid (**19**) was coupled to the same amine in a peptide coupling (**15**), followed by a TBDMS-deprotection (**16**) and a tosylation (**17**) of the compound. The tosylate **20** was then used in the substitution reaction, yielding AfBP LUF7909 (**4**) as a mixture of two rotamers, as determined by NMR and LCMS measurements.



Scheme 1. Synthesis of A₁AR-targeting AfBPs. Reagents and conditions: (a) Propargyl bromide (80% in toluene), K₂CO₃, acetone, reflux, overnight, 80-100%; (b) Malononitrile, thiophenol, Et₃N, EtOH, 50-75 °C, 4-10 h, 30-47%; (c) Isopentyl nitrite, CuCl₂, MeCN, 60 °C, 20 h, 72%; (d) Propargyl amine, dry THF, RT, overnight, 92%; (e) Potassium thioacetate, dry DMF, RT, 8 h, 99%; (f) **20**, NaHCO₃, dry DMF, 20-50 °C, 4 days, 40%; (g) (i) Potassium thioacetate, dry DMF, RT, 1-5 days; (ii) 2 M NaOH, RT, 1-3 days, 62-78%; (h) **20**, NaHCO₃, dry DMF, RT, 1-2 days, 29-53%; (i) TBDMS-Cl (50% in toluene), 1H-imidazole, dry DMF, RT, 5 h, quant.; (j) Propargylamine, DIPEA, MeCN, RT, 5 h, 52%; (k) **19**, EDC·HCl, DIPEA, dry DMF, RT, 3 days, 58%; (l) Et₃N·3HF, dry THF, RT, overnight, 92%; (m) TsCl, Et₃N, dry DMF, RT, 2 days, 55%; (n) NaHCO₃, dry DMF, RT, overnight, 31%; (o) Potassium bifluoride, H₂O, dioxane, 3 h, 95%; (p) 3-Bromopropylamine·HBr, Pybrop, DIPEA, dry DMF, RT, 12 days, 41%.

Evaluation of the AfBPs in radioligand binding assays and docking studies

With the molecules in hand, our attention was shifted towards the assessment of the potential probes' binding affinity towards the A₁AR, as well as the selectivity towards other adenosine receptors. The dicyanopyridine scaffold in particular is known to bind other adenosine receptor subtypes dependent on its substitutions.^[42,43] In a single point radioligand displacement assay using 1 μ M of probe at all four of the adenosine receptors, no considerable displacement of radioligand from the A_{2A}AR, A_{2B}AR and A₃AR was observed (Figure 2A). Probes **2** and **3** did not show considerable displacement of radioligand from the A₁AR, while **1** showed moderate (~70%) displacement and LUF7909 full (~100%) displacement. This indicates high affinity of LUF7909 towards the A₁AR and selectivity over the other adenosine receptors.

These differences can be rationalized by covalently docking the four ligands into the A₁AR binding pocket. Using the crystal structure of adenosine-bound A₁AR (PDB: 6D9H) and the binding pose of LUF7909 most similar (lowest RMSD) to the recently obtained crystal structure of structurally similar LUF5833 in the A_{2A}AR, a representative image was generated (Figure 3).^[44] From this pose, it was deduced that the methylenedioxy group of LUF7909 is located deep inside the binding pocket of the A₁AR. Substitutions at this position might therefore result in a loss in binding affinity, as observed for compounds **2** and **3**. Furthermore, the alkyne group of LUF7909 does not seem to hinder the important interactions that take place in the binding pocket (with residues F171, E172 and N254), thus explaining the high affinity.

Next, LUF7909 was submitted to a full curve radioligand displacement assay. To study the potential covalent binding mode of the probe, the assay was executed at two different time points, i.e. incorporating 0 or 4 hours of pre-incubation of probe with the receptor (Figure 2B). Without pre-incubation (0 h), LUF7909 showed an apparent pK_i of 7.8, while this increased to an apparent pK_i of 9.5 upon 4 hours of pre-incubation (Table S1). Such an increase in apparent pK_i (K_i shift of 44.0) is a strong indicator of a covalent mode of action. A wash-out experiment confirmed the persistent mode of binding of LUF7909 to the receptor, even after multiple washing steps (Figure S1). Besides that, LUF7909 acted as a partial agonist in a functional [³⁵S]GTP γ S assay (Figure S2), having a similar potency as the full agonist N⁶-cyclopentyladenosine (CPA) (pEC₅₀ of 8.7), but a significantly lower E_{max} (74%). Hence, LUF7909 behaves as a partial agonist that binds covalently, with high affinity and selectivity towards the A₁AR.




Figure 2. Affinities of LUF7909 and analogs for the four adenosine receptor subtypes. (A) Displacement of [³H]DPCPX (A₁AR), [³H]ZM241385 (A_{2A}AR), [³H]PSB-603 (A_{2B}AR) and [³H]PSB-11 binding (A₃AR) by 1 μ M of the respective AfBP. Data represent the values of two individual experiments performed in duplicate and are normalized to the vehicle control (100%). (B) Displacement of [³H]DPCPX from the A₁AR by LUF7909 measured after 0 or 4 hours of pre-incubation of LUF7909 with CHO membranes stably overexpressing the A₁AR. TB = total radioligand binding; NSB = non-specific radioligand binding. Data represent the mean $\pm$ SEM of three individual experiments performed in duplicate.




Figure 3. Top-down view of docked LUF7909 into the ligand binding pocket of the A₁AR. Crystal structure taken from the adenosine-bound A₁AR (PDB: 6D9H). The final ligand pose was selected based on the crystal structure of LUF5833 in the A_{2A}AR (PDB: 7ARO). Shown are the main amino acids that interact with LUF7909. The SO₂F-containing warhead is located close to tyrosine 271 (Y271), while the alkyne moiety is pointing outwards from the receptor.

Labeling of the A₁AR in SDS-PAGE experiments

As a first assessment of the labeling potential of our probe, SDS-PAGE experiments were carried out on CHO membranes that overexpress the A₁AR. Membranes were incubated with LUF7909 and subjected to click conjugation of probe to the fluorophore AF647-N₃. Samples were denatured, loaded on gel and the gel was visualized by in-gel fluorescence scanning. First, various concentrations of LUF7909 were investigated (Figure 4A). At roughly the apparent *K_i* of LUF7909 (16 nM at 0 h pre-incubation) a band at ~45 kDa appeared on the gel. Increasing the concentration of LUF7909 revealed additional labeling of a protein at ~30 kDa, where a probe concentration of 1 μM shows multiple extra proteins being labeled. This apparent non-specific binding at high concentrations is presumably due to the electrophilic nature of the fluorosulfonyl warhead.

The optimal balance between selective labeling and intensity of the observed bands seemed to occur at a concentration of 100 nM of LUF7909 (Table S2), which was therefore used in further SDS-PAGE experiments. Of note, no labeling was observed in the absence of copper(I) or probe during the click reaction (Figure 4B). Furthermore, the band at ~45 kDa disappeared upon pre-incubation with 1 μM of various A₁AR-selective ligands, such as the full agonist CPA (CP), partial agonist Capadenoson (CA), parent compound LUF7746 (LUF), reference antagonist DPCPX (D) and covalent antagonist FSCPX (F; structures in Figure S3). Western Blot experiments (Figure S4) further confirmed that the band at ~45 kDa, though slightly higher than the expected mass of the A₁AR (~36 kDa), is indeed the A₁AR.

The slightly higher mass can be explained by N-glycosylation of the A₁AR, as has been seen in early purification studies of endogenous A₁AR.^[45,46] Indeed, upon incubation with PNGase, a strong reduction is seen in molecular weight of the corresponding band (Figure 4C). Pre-incubation with the reversible antagonist DPCPX resulted in full disappearance of both bands, thereby confirming that this pattern represents the A₁AR.




Figure 4. Specific labeling of the A₁AR using LUF7909 in CHO membranes overexpressing the A₁AR. Membranes were pre-incubated with or without competitor, incubated with LUF7909, subsequently 'clicked' to AF647-N₃, denatured, subjected to SDS-PAGE and analyzed using in-gel fluorescence scanning. (A) Concentration-dependent labeling of the A₁AR. (B) Labeling of the A₁AR is dependent on the presence of copper(I) and probe during the click reaction, as well as the presence of known A₁AR ligands: agonist CPA (CP), partial agonist Capadenoson (CA), covalent partial agonist LUF7746 (L), antagonist DPCPX (D) and covalent antagonist FSCPX (F; structures in Figure S3). (C) Labeling of the A₁AR shows a strong reduction in molecular weight upon incubation with PNGase. Pre-incubation with 1 μ M of DPCPX shows full disappearance of both bands. CBB = Coomassie Brilliant Blue. The band that appears upon Coomassie staining (lane 3 and 4) corresponds to the molecular weight of PNGase.

Enrichment and detection of the A₁AR in chemical proteomics experiments

To further explore binding of LUF7909 to the A₁AR, as well as possible off-targets, chemical proteomics experiments were carried out. In brief, CHO cell membranes overexpressing the A₁AR were incubated with LUF7909. A concentration of 1 μ M was chosen to obtain a full proteomic profile of all the LUF7909-labeled proteins. Probe-bound proteins were 'clicked' to biotin-azide, denatured, precipitated, reduced, alkylated and pulled-down using streptavidin beads. The bound proteins were first washed and then digested. The obtained peptides were measured by LC-MS/MS. Initial attempts using Trypsin as digestion enzyme did not lead to detection of A₁AR-specific peptides. Therefore Chymotrypsin was chosen as digestion enzyme. Experiments without LUF7909 lead to detection of only one peptide of the A₁AR. However, upon affinity purification with LUF7909, an average sequence coverage of 40% of the receptor was detected by LC-MS/MS (Figure 5A; Table S2).

In the past years, considerable efforts have been done regarding the detection of GPCRs in chemical proteomics experiments.^[28,47–51] This includes mostly work using photoactivatable groups, such as diazirines and 2,5-disubstituted tetrazoles.^[28,47,50,52] To our knowledge, only one example of the use of an electrophilic ligand has been reported.^[51] Besides that, most of these experiments yielded a low sequence coverage when a non-purified receptor was measured. Only in case of the metabotropic glutamate receptors in brain slices, a higher sequence coverage was found.^[50] It is therefore remarkable that our experiment yielded an average sequence coverage of 40%. The detected peptides mostly include the non-membrane domains: C-terminus, N-terminus, intra- and extracellular loops.

Compared to DMSO-treated samples, a strong enrichment of the A₁AR (>200-fold) was observed (Figure 5B). This fold change was greatly reduced upon pre-incubation of the samples with 10 μ M of covalent ligand LUF7746 (Figure S5). Other proteins that showed a significant but substantially lower enrichment as compared to DMSO-treated samples were the G Protein subunit beta-1, malate dehydrogenase and ATPase subunit alpha. These off-targets might be the result of using a high concentration (1 μ M) of electrophilic probe in membrane fractions.




Figure 5. Proteomic detection of the A₁AR. (A) Snake plot of the adenosine A₁ receptor. Highlighted in blue are the peptides that were detected upon affinity purification using 1 μ M of LUF7909 in CHO_hA₁AR membranes. Amino acids highlighted in red are the glycosylation site (N159) and predicted probe binding site (Y271). Snake plot derived from gpcrdb.org.^[53] (B) Volcano plot of affinity purification experiments comparing samples treated with 1 μ M LUF7909 to samples containing DMSO as control. Plotted are the enrichment ratio (log₂(Ratio)) and the probability (-log₁₀(p)) as determined in a multiple *t* test. All data originate from six technical replicates. The Uniprot codes are given for proteins that meet a threshold value of ratio > 2 and p-value < 0.05 (dotted lines). These are the G protein subunit beta-1 (G3I1X8), malate dehydrogenase (G3HDQ2), sodium/potassium-transporting ATPase subunit alpha (G3H8Z9) and the adenosine A₁ receptor (P30542) (highlighted in red). Also shown in red is the Adenine Nucleotide Translocator (G3H777).

Investigation of the potential off-targets of LUF7909 in CHO_hA₁AR membrane fractions

In Figure 4 it is visible that a potential off-target of LUF7909 (concentrations up to 300 nM) has an approximate molecular mass of 30 kDa. This molecular weight does not correspond to any of the proteins that were significantly 'pulled-down' by LUF7909 during the chemical proteomics experiments. To further investigate this probable off-target, we performed similar chemical proteomics experiments, this time using CHO membrane fractions that do not overexpress the A₁AR. Contrary to the CHO_hA₁AR membranes, only small -fold changes were observed for the detected proteins (vs DMSO control) (Figure S6A). There are however two proteins that show a significant enrichment (>4): Elongation factor 1- α 1 and an isoform of the Adenine Nucleotide Translocator (ANT), the latter being an interesting target due to its binding of adenine-containing substrates. We therefore pre-incubated both CHO and CHO_hA₁AR membranes with various concentrations of bongkreik acid, a known inhibitor of ANT,^[54] prior to the sequential addition of LUF7909, clicking to AF647-N₃ subjecting to SDS-PAGE and scanning using in-gel fluorescence (Figure S6B).

Pre-incubation with bongkreik acid resulted in a concentration-dependent inhibition of the band observed for the 'empty' CHO membranes, as well as the lower band observed for the CHO_hA₁AR membranes. This suggests that the extra band seen on gel corresponds to ANT. Also the pull-down experiments with LUF7909 in CHO_hA₁AR membranes show the presence

of ANT (Figure 5B), although not significantly enriched compared to the DMSO control samples (fold change of 1.2). The reason for this may be the high expression level of ANT in mitochondria,^[55] causing an enrichment of ANT in our membrane fractions. We assume that binding of LUF7909 to ANT occurs because of a high concentration of ANT in combination with the electrophilic nature of the probe.

Labeling of the A₁AR on live cells

Moving a step closer to a more endogenous system, we tested the labeling properties of LUF7909 in live CHO cells. First, CHO cells with or without overexpression of the A₁AR were incubated with 100 nM of probe, prior to membrane collection and click reaction with AF647-N₃. The samples were denatured, loaded on SDS-PAGE and analyzed using in-gel fluorescence (Figure 6A and S7). A 'smear' was observed at the height of the A₁AR, which was not present upon pre-incubation with DPCPX (1 μM). This smear is presumably due to different glycosylation states of the A₁AR. No other strong bands were detected, both in the CHO cells with and without overexpression of the A₁AR. Secondly, affinity-based pull-down experiments were performed using live CHOhA₁AR cells. Again, a high enrichment of the A₁AR was found (Figure 6B), however less labeling of other proteins compared to the experiments with membrane fractions. It thus seems that labeling of the A₁AR by LUF7909 is more specific in live CHOhA₁AR cells, as compared to labeling in membrane fractions derived from these CHOhA₁AR cells (Figure 4 and 5).

To confirm these observations, labeling of the receptor in live CHO cells was studied using confocal microscopy. Live CHO cells with or without overexpression of the A₁AR were incubated with LUF7909 and subsequently fixed. The probe-bound proteins were stained with TAMRA-N₃ (via a click reaction) and the cellular nuclei were stained with DAPI. As compared to the DMSO control, LUF7909 showed clear labeling of cell-cell contacts and cellular membranes by TAMRA-N₃ (Figure 6C). The degree of labeling was diminished by pre-incubation with 1 μM of covalent ligand FSCPX, and absent upon using CHO cells that do not overexpress the A₁AR. These controls confirm that the observed labelling, in gel, LC-MS/MS and under the microscope, is indeed due to selective labeling of the A₁AR and not an off-target protein. Furthermore, signs of A₁AR labeling inside the cells were observed in Figure 6C. The reason for this might be internalization, an effect that has been reported to take place upon incubating the A₁AR with an agonist.^[56] Having a clickable (partial) agonist thus allows further studies towards receptor internalization.

Labeling of LUF7909 in cells endogenously expressing the A₁AR

Having established labeling of the A₁AR in CHOhA₁AR membranes and live cells, we attempted to label the receptor in membrane fractions that endogenously contain the A₁AR as a next step. For this, we used membranes derived from adipocytes: a cell type that is known to express the A₁AR.^[7,58] Adipocyte membranes were collected from gonadal fat pads from female mice and subsequently incubated with 100 nM LUF7909, deglycosylated with PNGase, clicked to AF647-N₃, denatured, resolved by SDS-PAGE and analyzed using in-gel fluorescence scanning. This resulted in multiple bands (Lane 1, Figure 7) at molecular weights of roughly 90, 65 and 60 kDa, and a smear of presumably two bands at 30 kDa. The intensity of the bands at 30 kDa (indicated with an arrow) is strongly diminished upon pre-incubation with 1 μM of the selective covalent A₁AR antagonist FSCPX. Full reduction of this band was observed when using a high concentration of FSCPX (Figure S9A), which gives a strong indication that this band is in fact the A₁AR. The band at ~30 kDa (lane 1) shows a great difference in mass compared to observed A₁AR in CHO cells. The presumable reason for this is a difference in glycosylation pattern of the receptors, an effect that has also been observed when comparing the A₁AR from brain to the A₁AR from testis.^[45]




Figure 6. Selective labeling of the A₁AR in live CHO cells. (A) CHO cells with or without overexpression of the A₁AR were pre-treated for 1 h with DPCPX (1 μ M) or 1% DMSO and incubated for 1 h with LUF7909 (100 nM) or 1% DMSO (control). Membranes were collected, treated with PNGase and incubated with click mix containing AF647-N₃. The samples were then subjected to SDS-PAGE and analyzed by in-gel fluorescence scanning. CBB = Coomassie Brilliant Blue. (B) Volcano plot of affinity purification experiments comparing live CHO^hA₁AR cells treated with 1 μ M LUF7909 to cells treated with 1% DMSO (control). All data originate from six technical replicates. Shown is the uniprot code for the A₁AR (P30542) (highlighted in red). (C) Confocal microscopy images. CHO cells with or without overexpression of the A₁AR were pre-treated for 1 h with FSCPX (1 μ M) or 1% DMSO and incubated for 1 h with of LUF7909 (100 nM) or 1% DMSO (control). The cells were then fixed and stained with TAMRA-N₃ (first row) and DAPI (second row). The third row shows an overlay of both stains. TAMRA = red, DAPI = blue. Arrows indicate examples of labeled membranes and labeling inside cells. Images were selected manually as representatives of blinded measurements from two separate experiments (see Figure S8). Scale bar = 10 μ m. Figure was created using OMERO.^[57]




Figure 7. Labeling of the A₁AR in adipocyte membranes derived from mouse gonadal fat pads. The membranes were pre-treated with the covalent antagonist FSCPX (1 μ M) or 1% DMSO prior to incubation with LUF7909 (100 nM) and subsequent incubation with click mix containing AF647-N₃. The samples were then denatured, subjected to SDS-PAGE and analyzed using in-gel fluorescence scanning. CBB = Coomassie Brilliant Blue. The band that appears upon Coomassie staining (lane 3 and 4) corresponds to the molecular weight of PNGase.

Besides the A₁AR, LUF7909 also labeled multiple off-target proteins in these experiments, e.g. the bands at ~90 and ~65 kDa. Preliminary experiments showed a clear reduction in intensity for the band at ~90 kDa upon pre-incubation with a protease inhibitor cocktail (Figure S9B). This would indicate off-target binding to a presumable protease. We did not further examine this finding. The labeling and visualization of low-abundant GPCRs in SDS-PAGE experiments thus seems to be challenging when high levels of potential off-targets are present. For future studies using AfBPs we therefore suggest to perform affinity-based pull-down proteomics, confocal microscopy or flow cytometry experiments to investigate GPCRs on native cells and tissues.

Conclusion

In this study we have described the design and synthesis of LUF7909, a versatile probe molecule acting as a partial agonist that was used to characterize the A₁AR in a broad spectrum of assays. LUF7909 showed labeling of the A₁AR at about its apparent K_i , as well as labeling of other proteins in SDS-PAGE experiments. The observed off-targets on gel were not significantly enriched in proteomic studies, nor found in live cell experiments, both carried out in A₁AR overexpressing cells. In the latter two types of experiments, LUF7909 proved to be highly specific towards the A₁AR.

Altogether, this work shows various methods to implement AfBPs within the broad field of GPCR research. This paves the way towards an investigation of more physiologically relevant processes, e.g. the presence/absence of PTMs on GPCRs (through LC-MS/MS investigations) and receptor internalization (through confocal microscopy). This will ultimately help to get a better understanding of GPCRs in both physiological and pathological conditions, opening up new avenues for drug discovery in general.

Acknowledgements

We thank P.C.N. Rensen and M. Sch6nke (LUMC, Leiden, The Netherlands) for their kind donation of female mouse gonadal fat pads. We also thank I. Boom (LACDR, Leiden, The Netherlands) for performing high-resolution mass spectrometry measurements. The authors gratefully acknowledge the imaging core facility, the Leiden University Cell Observatory, for their support and assistance in this work.

Supporting Tables

Table S1. Time-dependent characterization of the affinity of LUF7909.

Compound	pKi (0 h) ^a	pKi (4 h) ^b	Ki shift ^c
LUF7909	7.8 ± 0.04	9.5 ± 0.01	44.0 ± 5.1

Values represent apparent pKi ± SEM (n = 3) of individual experiments each performed in duplicate. ^a Affinity determined from displacement of specific [³H]DPCPX binding on CHO cell membranes stably expressing hA₁AR at 25 °C after 0.5 h co-incubation; ^b Affinity determined from displacement of specific [³H]DPCPX binding on CHO cell membranes stably expressing hA₁AR at 25 °C with compounds pre-incubated for 4 h, followed up by a 0.5 h co-incubation with [³H]DPCPX. ^c Ki shift determined by ratio Ki(0 h)/Ki(4 h).

Table S2. Concentration-dependent labeling by LUF7909 in SDS-PAGE experiments. A concentration of 100 nM LUF7909 shows both a high intensity (70% intensity compared to the band at 1000 nM) and a low degree of off-target labeling (11%).

Concentration LUF7909 (nM)	Relative band intensity (%) ^a	A ₁ AR labeling vs. off-target labeling (%) ^b
1	1 ± 0	31 ± 10
3	5 ± 1	84 ± 6
10	16 ± 6	86 ± 5
30	44 ± 12	95 ± 1
100	70 ± 9	89 ± 4
300	90 ± 14	74 ± 8
1000	100	51 ± 13

Values represent the mean percentage ± SEM (n = 3). Band intensities were determined with ImageLab software, using the gel images from Figure S3A. ^a The adjusted volumes of the bands were taken and corrected for the amount of protein after Coomassie staining. The highest band intensity (1000 nM probe) was set to 100%; ^b The bands at approx. 45 kDa (A₁AR) and approx. 30 kDa were selected in each lane and band percentages were calculated by ImageLab. The value in the table shows the percentage of the upper band (band 45 kDa (%) + band 30 kDa (%) = 100 (%)).

Table S3. Detected A₁AR peptides upon affinity purification using LUF7909 in CHO membranes that overexpress the A₁AR.

Sequence	Length	m/z	Charges	Start position	End position	Peptide score ^a
MPPSISAF	8	848.4102	1	1	8	150.82
PPSISAF	7	717.3697	1	2	8	131.42
AVKVNQALRDATAF	13	1431.783	3	33	45	58.781
INIGPQTY	8	904.4654	1	69	76	176.41
MVACPVIL	9	1014.561	2	82	90	97.306
ALLAIAVDY	10	1103.634	2	97	106	78.334
LAIAVDY	8	919.5127	2	99	106	104.45
AIADVY	7	806.4287	2	100	106	103.29
VVTPRRAAVAIAGCW	15	1625.882	2;3	118	132	58.676
NNLSAVERAW	10	1158.578	2	147	156	131.44
NKKVSASSGDPQKY	14	1507.763	2;3	212	225	197.3
NKKVSASSGDPQKY	15	1670.826	2;3	212	226	156.51
FCPSCHKPSIL	11	1344.632	3	259	269	47.559
CPSCHKPSIL	10	1197.563	2;3	260	269	128.6
LTHGNSAMNPVY	13	1415.687	2	276	288	156.83
THGNSAMNPVY	12	1302.603	2	277	288	157.96
LKIWNDFH	8	1071.55	2;3	300	307	120.65
KIWNDFH	7	958.4661	2	301	307	158.38
RCQPAPPIDEDLPEERPDD	19	2248.007	2;3	308	326	218.16

^aAs determined by MaxQuant.

Supporting Figures




Figure S1 Wash-out assay reveals persistent binding of LUF7909 to the A₁AR. Membranes derived from CHO cells transiently transfected with the A₁AR were pre-incubated with buffer (vehicle) or 1 μM LUF7909, followed by a four cycle washing treatment or no washing at all before being exposed to [³H]DPCPX in a standard radioligand binding assay. Data is expressed as the percentage of the vehicle group (100%) and represents the mean ± SEM of three individual experiments performed in duplicate.




Figure S2 Functional characterization of LUF7909 in a [³⁵S]GTPγS binding assay. Concentration-dependent functional-effect curve of CPA and LUF7909 using membranes derived from CHO cells that were stably transfected with the hA₁AR. Data is expressed as a percentage of the maximal response induced by 100 nM CPA and the mean ± SEM of three individual experiments performed in duplicate. **p < 0.01 as compared to the E_{max} value of CPA, determined by a two-tailed unpaired Student's *t*-test.




Figure S3. Molecular structures of the selective A₁AR ligands used in this study: full agonist *N*⁶-cyclopentyladenosine (CPA), partial agonist Capadenoson, covalent partial agonist LUF7746, antagonist DPCPX and covalent antagonist FSCPX.




Figure S4. Verification of A₁AR labeling by LUF7909. Figures show SDS-PAGE and Western Blot experiments (left side), as well as N=3 data (right side). Conditions for A-D were the same as in Figure 4. The gel was transferred to a 0.2 μ m PVDF blot using a Trans-Blot Turbo Transfer System (Bio-Rad)(2.5 A, 7 min) or stained with Coomassie Brilliant Blue (CBB). Blots were blocked with 5% BSA in TBST (1 h, rt), incubated with primary antibody (rabbitratA₁AR 1:5000 in 1% BSA in TBST)(4 $^{\circ}$ C, overnight), washed (3 x TBST), incubated with secondary antibody (goat-rabbit-HRP 1:2000 in 1% BSA in TBST)(1h, rt), washed (2 x TBST, 1 x TBS), activated with luminol enhancer and peroxide (3 min, rt, dark) and subsequently scanned on fluorescence and chemiluminescence. (D) Quantification of the amount of LUF7909 displaced by 1 μ M of the respective covalent ligand. Values represent the mean percentage $\pm$ SEM (n = 3). Band intensities were determined with ImageLab software using the gel images from Figure S4B. The adjusted volumes of the bands were taken and corrected for the amount of protein after Coomassie staining. The band intensity of lane 4 (no competitor) was set to 0%.




Figure S5. The adenosine A₁ receptor does not show a strong enrichment upon pre-incubation of the samples with **LUF7746**. Volcano plot of affinity purification experiments comparing samples treated with 1 μ M **LUF7909** to samples that were pre-treated with 10 μ M of **LUF7746**. Plotted are the enrichment ratio ($\log_2(\text{Ratio})$) and the probability ($\log_{10}(p)$) as determined in a multiple t test. All data originate from six technical replicates. The Uniprot codes are given for proteins that meet a threshold value of ratio > 2 and p-value < 0.05 (dotted lines). These are the Splicing factor 3B subunit 1 (G3HL16), Nuclear pore complex protein Nup96 (G3I3B3), Lamin-A/C (G3HG95), Catalase (G3GYY6) and Protein RCC2 (G3IJB6). The adenosine A₁ receptor (P30542) is highlighted in red.




Figure S6. Off-target investigation of the proteins labeled by **LUF7909**. (A) Volcano plot of affinity purification experiments comparing samples of CHO membrane fractions (not overexpressing the A_1AR) treated with 1 μM **LUF7909** to samples treated with 1% DMSO. Plotted are the enrichment ratio ($\log_2(Ratio)$) and the probability ($\log_{10}(p)$) as determined in a multiple t test. All data originate from six technical replicates. The Uniprot codes are given for proteins that meet a threshold value of $ratio > 2$ and $p\text{-value} < 0.05$ (dotted lines). These are the Adenine Nucleotide Translocator (ANT)(G3H777) and Elongation factor 1-alpha 1 (G3HH39). (B) SDS-PAGE experiments show a concentration-dependent inhibition of the lower band by the ANT-inhibitor bongkreikic acid (**BA**) (N=3). CHO membrane fractions with and without overexpression of the A_1AR were pre-incubated with various concentrations of **BA**, prior to incubation with 100 nM of **LUF7909**. The samples were then clicked to AF647- N_3 , denatured, resolved by SDS-PAGE and scanned using in-gel fluorescence. Coomassie Brilliant Blue (CBB) was used as protein loading control. (C) Quantification of **LUF7909** displacement by **BA**. Values represent the mean percentage $\pm$ SEM (graph) or apparent affinity $\pm$ SEM (table) ($n = 3$). Band intensities were determined with ImageLab software using the gel images from Figure S6B. The adjusted volumes of the bands were taken and corrected for the amount of protein after Coomassie staining. The band intensity of lane 1 (no **BA**) was set to 100%.






Figure S7 Additional SDS-PAGE experiments supporting Figure 6. Figure shows SDS-PAGE and Western Blot experiments (left side), as well as N=3 data (right side). Live CHO_hA₁AR and non-transfected CHO cells were pre-treated with DPCPX (1 μ M) or 1% DMSO and incubated with **LUF7909** (100 nM) or 1% DMSO (control). Membranes were collected and incubated with click mix containing AF647-N₃. The samples were then subjected to SDS-PAGE and analyzed by in-gel fluorescence scanning. The gel was transferred to a 0.2 μ m PVDF blot using a Trans-Blot Turbo Transfer System (Bio-Rad)(2.5 A, 7 min) or stained with Coomassie Brilliant Blue (CBB). The blot was blocked with 5% BSA in TBST (1 h, rt), incubated with primary antibody (rabbit_{rat}A₁AR 1:5000 in 1% BSA in TBST)(4 $^{\circ}$ C, overnight), washed (3 x TBST), incubated with secondary antibody (goat_{rat}HRP 1:2000 in 1% BSA in TBST)(1h , rt), washed (2 x TBST, 1 x TBS), activated with luminol enhancer and peroxide (3 min, rt, dark) and subsequently scanned on fluorescence and chemiluminescence.


A



B



C



D





Figure S8. Additional confocal microscopy images supporting Figure 6C. CHO cells with or without overexpression of the A₁AR were pre-treated for 1 h with irreversible antagonist FSCPX (1 μ M) or 1% DMSO and incubated for 1 h with LUF7909 (100 nM) or 1% DMSO (control). The cells were then fixed and stained with TAMRA-N₃ (panel A; shown in the red channel) and DAPI (panel B; shown in the blue channel). FOV = Field of view. Images were acquired automatically from two biological experiments performed in duplicate. Shown are four of the FOVs from each of the imaged plates, selected based on a similar amount of cells present in the FOV (FOV 1-4: experiment 1; FOV 5-8: experiment 2). Scale bar = 10 μ m. Panel was created using OMERO. (C) Example of automated image analysis of the total intensity of the Tamra-N₃ signal per single cell with and without treatment with LUF7909. Total fluorescence intensity in the cytoplasm of single cells was quantified using CellProfiler. (D) Comparison of the fluorescence intensities between treatment conditions in experiment 2. One single dot represent one single cell. A significant increase in intensity is observed for the cells containing the A₁AR, treated with LUF7909, without competing ligand versus those cells not treated with LUF7909.

4

A



B




Figure S9 Labeling of LUF7909 in membranes derived from rat adipocytes. The membranes were pre-incubated with competing ligand (25 μ M FSCPX or 1 μ L protease inhibitor cocktail (PIC), prior to incubation with 100 nM LUF7909. The samples were then incubated with PNGase, clicked to AF647-N₃, denatured and resolved by SDS-PAGE. The gels were scanned using in-gel fluorescence. (A) Competition with 25 μ M of covalent antagonist FSCPX; (B) Intensity of the band at 90 kDa is reduced upon pre-incubation with 1 μ L of PIC (Sigma Aldrich, cat # p8340).


Experimental

Chemistry

General


All commercially available reagents and solvents were obtained from Sigma Aldrich, Fisher Scientific, VWR chemicals, and Biosolve. All reactions were carried out under a N₂ atmosphere in oven-dried glassware. Thin layer chromatography was performed on TLC Silica gel 60 F254 (Merck) and visualized using UV irradiation. Silica gel flash chromatography was performed using 60-200 μ m 60 Å silica gel (VWR Chemicals). ¹H-NMR spectra were recorded on a Bruker AV-300 (300 MHz), Bruker AV-400 (400 MHz) or a Bruker AV-500 spectrometer (500 MHz). ¹³C-NMR spectra were recorded on a Bruker AV-400 (101 MHz) or a Bruker AV-500 (126 MHz) spectrometer. ¹⁹F-NMR spectra were recorded on a Bruker AV-500 spectrometer (471 MHz). Chemical shift values are reported in ppm (δ) using tetramethylsilane or solvent resonance as the internal standard. Coupling constants (J) are reported in Hz. Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (pentuplet) or m (multiplet) followed by the number of represented hydrogen atoms. Compound purity was determined by LC-MS, using the LCMS-2020 system of Shimadzu coupled to a Gemini® 3 μ m C18 110Å column (50 x 3 mm). In brief, compounds were dissolved in H₂O:MeCN:*t*-BuOH 1:1:1, injected onto the column and eluted with a linear gradient of H₂O:MeCN 90:10 + 0.1% formic acid $\rightarrow$ H₂O:MeCN 10:90 + 0.1% formic acid over the course of 15 minutes. High-resolution mass spectrometry (HRMS) was performed on a X500R QTOF mass spectrometer (SCIEX). Reaction schemes were created with ChemDraw Professional version 16.0.0.82 (PerkinElmer).

Synthetic Procedures



3-Methoxy-4-(prop-2-yn-1-yloxy)benzaldehyde (**6a**)


3-methoxy-4-hydroxy benzaldehyde (3.80 g, 25.0 mmol, 1.0 eq), propargyl bromide (80% in toluene) (8.30 ml, 74.5 mmol, 3.0 eq) and K₂CO₃ (5.18 g, 37.5 mmol, 1.5 eq) were dissolved in acetone (250 mL). The mixture was refluxed overnight, after which a precipitate had formed. The precipitate was filtrated, dried under reduced pressure and purified by flash column chromatography (PE/EtOAc 95:5 $\rightarrow$ 70:30) to yield **6a** (3.80 g, 20.0 mmol, 80%) as a white solid. **TLC** (PE/EtOAc 7:3): R_f = 0.57. **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 9.87 (s, 1H), 7.46 (dd, *J* = 8.2, 1.9 Hz, 1H), 7.43 (d, *J* = 1.9 Hz, 1H), 7.14 (d, *J* = 8.2 Hz, 1H), 4.86 (d, *J* = 2.4 Hz, 2H), 3.94 (s, 3H), 2.56 (t, *J* = 2.4 Hz, 1H).



4-Methoxy-3-(prop-2-yn-1-yloxy)benzaldehyde (**6b**)


3-hydroxy-4-methoxybenzaldehyde (608 mg, 4.00 mmol, 1.0 eq) and K₂CO₃ (830 mg, 6.01 mmol) were dissolved in acetone (20 mL). Propargylbromide (80% in toluene) (1.33 mL, 12.0 mmol, 3.0 eq) was added and the solution was refluxed for 1 h at 80 °C and allowed cooled down to rt overnight. Water (40 mL) was added and the mixture was extracted with EtOAc (3 x 40 mL). The organic layers were combined and washed with brine (1 x 50 mL), dried over

MgSO₄ and evaporated to yield **6b** (759 mg, 3.99 mmol, 100 %) as an off-white oil. **TLC** (PE/EtOAc 3:2): *R*_f = 0.67. **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 9.66 (s, 1H), 7.42 – 7.27 (m, 2H), 6.83 (d, *J* = 8.1 Hz, 1H), 4.64 (d, *J* = 2.5 Hz, 2H), 3.76 (s, 3H), 2.50 (t, *J* = 2.4 Hz, 1H). **¹³C NMR** (101 MHz, CDCl₃): δ [ppm] = 190.3, 154.5, 146.9, 129.5, 126.9, 111.5, 110.7, 77.6, 76.4, 56.2, 55.8.




2-Amino-4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (**7a**)

Et₃N (140 μL, 1.00 mmol, 0.05 eq) was added dropwise to a suspension of **6a** (3.80 g, 20.0 mmol, 1.0 eq) and malononitrile (2.73 g, 41.3 mmol, 2.1 eq) in EtOH (30 mL). The mixture was brought to 50 °C, upon which thiophenol (2.18 mL, 21.3 mmol, 1.1 eq) was added. The mixture was then stirred at 50 °C for 4 h, after which TLC revealed full consumption of the aldehyde. The mixture was cooled down to rt and the formed precipitate was collected by filtration to yield **7a** (3.87 g, 9.38 mmol, 47%) as an off-white solid. **TLC** (PE/EtOAc 7:3): *R*_f = 0.27. **¹H NMR** (400 MHz, (CD₃)₂SO): δ [ppm] = 7.78 (s, 2H), 7.63 – 7.58 (m, 2H), 7.55 – 7.46 (m, 3H), 7.28 – 7.23 (m, 1H), 7.21 – 7.11 (m, 2H), 4.90 (d, *J* = 1.8 Hz, 2H), 3.81 (s, 3H), 3.64 (t, *J* = 2.1 Hz, 1H).




2-Amino-4-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (**7b**)

Malononitrile (264 mg, 3.99 mmol, 1.0 eq) and piperidine (catalytic amount) were added to a solution of **6b** (759 mg, 3.99 mmol, 1.0 eq) in EtOH (5 mL) at 50 °C. The mixture immediately became a yellow suspension. The mixture was refluxed at 50 °C for 5 h and afterwards cooled down to rt. The formed precipitate was filtrated and dried under reduced pressure to yield 611 mg (2.56 mmol) of the malononitrile-substituted intermediate. This crude intermediate was then re-dissolved in EtOH (10 mL) by heating the mixture to 65 °C. Malononitrile (190 mg, 2.88 mmol, 1.4 eq) and triethylamine (catalytic amount) were added and the solution was refluxed for 45 min at 65 °C. Thiophenol (288 μL, 2.82 mmol, 0.7 eq) was added and the solution was refluxed for 3 h at 65 °C, upon which TLC showed full consumption of the starting material. The mixture was cooled down to rt and allowed to crystallize overnight. The formed precipitate was collected by filtration and dried under reduced pressure to yield **7b** (500 mg, 1.21 mmol, 30% yield). **TLC** (PE/EtOAc 7:3): *R*_f = 0.22. **¹H NMR** (300 MHz, CDCl₃): δ [ppm] = 7.59 – 7.52 (m, 2H), 7.50 – 7.44 (m, 3H), 7.25 – 7.20 (m, 2H), 7.04 (d, *J* = 9.0 Hz, 1H), 5.43 (s, 2H), 4.83 (d, *J* = 2.4 Hz, 2H), 3.95 (s, 3H), 2.59 (t, *J* = 2.4 Hz, 1H). **LCMS** (ESI, *m/z*): [M+H]⁺: 413.15. **HPLC**: 100%, RT 10.893 min.




2-Amino-4-(benzo[d][1,3]dioxol-5-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (**7c**)

Piperonal (3.00 g, 20.0 mmol, 1 eq) was added to a solution of malononitrile (1.32 g, 20.0 mmol, 1.0 eq) in EtOH (20 ml). Piperidine (catalytic amount) was added and the solution was refluxed at 75 °C for 3 h, before slowly cooling down to RT. The formed yellow precipitate was collected by filtration, washed with EtOH and water and dried under reduced pressure to yield the malononitrile-substituted intermediate (3.72 g, 18.80 mmol). 1 gram of the crude intermediate was taken for the further steps (1.00 g, 5.05 mmol, 1.0 eq) and dissolved in EtOH (10 ml). Malononitrile (364mg, 5.51 mmol, 1.1 eq), thiophenol (567 μ L, 5.56 mmol, 1.1 eq) and triethylamine (catalytic amount) were added and the mixture was refluxed at 75 °C for 10 h before slowly cooling down to rt. The formed yellow precipitate was collected by filtration and the residue was purified by automated flash column chromatography (DCM/MeOH 99:1 $\rightarrow$ 95:5). The precipitate and the purified filtrate were combined to yield **7c** (885 mg, 2.38 mmol, 44% over two steps) as a yellow solid. **TLC** (PE/EtOAc 7:3): R_f = 0.27. **$^1\text{H NMR}$** (300 MHz, CDCl_3): δ [ppm] = 7.58 – 7.52 (m, 2H), 7.50 – 7.43 (m, 3H), 7.04 (dd, J = 8.0, 1.8 Hz, 1H), 6.99 (d, J = 1.7 Hz, 1H), 6.96 (d, J = 8.0 Hz, 1H), 6.08 (s, 2H), 5.43 (s, 2H). **LCMS** (ESI, m/z): $[\text{M}+\text{H}]^+$: 373.10. **HPLC**: 100%, RT 10.924 min.



4-(Benzo[d][1,3]dioxol-5-yl)-2-chloro-6-(phenylthio)pyridine-3,5-dicarbonitrile (**8**)


Isopentyl nitrite (403 μ L, 3.00 mmol, 1.4 eq) and copper(II)chloride (402 mg, 2.99 mmol, 1.4 eq) were added to a solution of **7c** (797 mg, 2.14 mmol, 1.0 eq) in acetonitrile (10 ml). The mixture was refluxed at 60 °C for 20 h and afterwards slowly cooled down to rt. 1 M HCl (30 mL) was added and the resulting green aqueous layer was extracted with DCM (4 x 30 mL). The organic layers were combined, dried over MgSO_4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (PE/EtOAc 9:1 $\rightarrow$ 7:3) to yield **8** (606 mg, 1,547 mmol, 72 % yield). **TLC** (PE/EtOAc 7:3): R_f = 0.63. **$^1\text{H NMR}$** (400 MHz, CDCl_3): δ [ppm] = 7.64 – 7.44 (m, 5H), 7.06 (dd, J = 8.0, 1.9 Hz, 1H), 7.01 – 6.98 (m, 2H), 6.10 (s, 2H). **$^{13}\text{C NMR}$** (101 MHz, CDCl_3) δ 169.3, 158.5, 156.1, 150.8, 148.6, 135.7, 130.8, 129.8, 125.8, 125.2, 123.9, 113.7, 113.4, 109.3, 109.0, 106.3, 105.0, 102.3. **LCMS** (ESI, m/z): $[\text{M}+\text{H}]^+$: 392.00. **HPLC**: 100%, RT 11.892 min.



4-(Benzo[d][1,3]dioxol-5-yl)-2-(phenylthio)-6-(prop-2-yn-1-ylamino)pyridine-3,5-dicarbonitrile (**9**)


Propargyl amine (90 μ L, 1.41 mmol, 2 eq) was added to a solution of **8** (274 mg, 0.699 mmol) in dry THF (3.5 ml) and the mixture was stirred at rt overnight. Water (25 mL) was then added and the aqueous layer was extracted with DCM (2 x 25 mL). The organic layers were combined

and washed with 1 M HCl (2 x 25 mL) and brine (25 mL), dried over MgSO₄, filtered and concentrated under reduced pressure to yield **9** (265 mg, 0.65 mmol, 92%) as a yellow solid. **TLC** (Pentane/EtOAc 8:2): *R_f* = 0.31. **¹H NMR** (500 MHz, CDCl₃): δ [ppm] = 7.59 (dd, *J* = 7.9, 1.7 Hz, 2H), 7.53 – 7.41 (m, 3H), 7.01 (dd, *J* = 8.0, 1.9 Hz, 1H), 6.97 (d, *J* = 1.8 Hz, 1H), 6.94 (d, *J* = 8.0 Hz, 1H), 6.05 (s, 2H), 5.83 (t, *J* = 5.5 Hz, 1H), 3.74 (dd, *J* = 5.5, 2.5 Hz, 2H), 2.18 (t, *J* = 2.5 Hz, 1H). **¹³C NMR** (126 MHz, CDCl₃): δ [ppm] = 169.3, 157.7, 156.9, 150.0, 148.2, 136.2, 130.1, 129.3, 127.2, 126.7, 123.3, 115.3, 115.1, 109.0, 108.9, 102.0, 95.1, 88.1, 78.9, 71.9, 30.9.



4-(Benzo[d][1,3]dioxol-5-yl)-2-mercapto-6-(prop-2-yn-1-ylamino)pyridine-3,5-dicarbonitrile (**10**)


Potassium thioacetate (178 mg, 1.56 mmol, 2.0 eq) was added to a solution of **9** (321 mg, 0.78 mmol, 1.0 eq) in dry DMF (4 mL). After 6 h of stirring, 2.0 equivalent of potassium thioacetate (178 mg, 1.56 mmol) was added and the mixture was stirred for another 2 h, upon which the TLC indicated full consumption of starting material. EtOAc (50 mL) was added and the organic layer was washed with brine (3 x 50 mL), dried over MgSO₄, filtered and concentrated under reduced pressure to yield **10** as a yellow/brown solid (258 mg, 0.77 mmol, 99%), which was used in the next steps without further purification. **TLC** (DCM:MeOH 95:5): *R_f* = 0.18. **¹H NMR** (500 MHz, (CD₃)₂SO) δ [ppm] = 8.71 (t, *J* = 5.6 Hz, 1H), 7.22 (d, *J* = 1.8 Hz, 1H), 7.18 – 7.09 (m, 2H), 6.21 – 6.11 (m, 3H), 4.08 (dd, *J* = 5.7, 2.5 Hz, 2H), 2.81 (t, *J* = 2.4 Hz, 1H). **¹³C NMR** (126 MHz, (CD₃)₂SO) δ [ppm] = 162.4, 158.1, 157.0, 149.3, 147.5, 126.7, 123.4, 114.9, 114.6, 109.0, 108.7, 101.9, 93.8, 89.8, 89.1, 72.0, 30.6. **LCMS** (ESI, *m/z*): [*M*+H]⁺: 334.95.



4-((3-((4-(Benzo[d][1,3]dioxol-5-yl)-3,5-dicyano-6-(prop-2-yn-1-ylamino)pyridin-2-yl)thio)propyl)carbamoyl)benzenesulfonyl fluoride (**1**)


19 (350 mg, 1.08 mmol, 1.4 eq) and NaHCO₃ (97 mg, 1.16 mmol, 1.5 eq) were added to a solution of **10** (258 mg, 0.77 mmol, 1.0 eq) in dry DMF (3.4 mL). The mixture was stirred for 2 days, after which another 1.5 eq of NaHCO₃ (97 mg, 1.16 mmol) was added. The mixture was then stirred at 50 °C for two days. DCM (50 mL) was added and the organic layer was washed with brine (3 x 50 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography (DCM:MeOH 99.5:0.5 → 99:1) and recrystallization in DCM to yield **1** as a yellow solid (177 mg, 0.31 mmol, 40%). **TLC** (DCM:MeOH 99:1): *R_f* = 0.38. **¹H NMR** (500 MHz, (CD₃)₂SO) δ [ppm] = 8.95 (t, *J* = 5.6 Hz, 1H), 8.56 (t, *J* = 5.6 Hz, 1H), 8.26 (d, *J* = 8.6 Hz, 2H), 8.19 (d, *J* = 8.5 Hz, 2H), 7.18 (d, *J* = 1.8 Hz, 1H), 7.10 (d, *J* = 8.0 Hz, 1H), 7.05 (dd, *J* = 8.1, 1.8 Hz, 1H), 6.15 (s, 2H), 4.21 (dd, *J* = 5.6, 2.4 Hz, 2H), 3.46 (q, *J* = 6.4 Hz, 2H), 3.38 (t, *J* = 6.9 Hz, 2H), 3.09 (t, *J* = 2.4 Hz, 1H), 2.04 (p, *J* = 6.9 Hz, 2H). **¹³C NMR** (126 MHz, (CD₃)₂SO) δ [ppm] = 167.2, 164.5, 157.6, 157.0, 149.0, 147.4, 141.5, 133.4 (d, *J* = 23.8 Hz), 129.1, 128.6, 127.2, 123.1, 115.4, 115.0, 109.0, 108.6, 101.8, 94.4, 87.4, 80.8, 72.8, 38.6, 30.9, 29.1, 27.7. **¹⁹F NMR** (471 MHz, (CD₃)₂SO) δ [ppm] = 65.94.

HRMS (ESI, m/z): $[M+H]^+$, calculated: 578.0963, found: 578.0970. **HPLC**: 99%, RT 11.262 min.




2-Amino-6-mercapto-4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)pyridine-3,5-dicarbonitrile (11a)

Potassium thioacetate (65 mg, 0.57 mmol, 2.4 eq) was added to a solution of **7a** (99 mg, 0.24 mmol, 1.0 eq) in dry DMF (2 mL). The mixture was stirred for 6 h, after which extra potassium thioacetate (65 mg, 0.57 mmol, 2.4 eq) was added. The mixture was stirred overnight and another 2.4 equivalent of potassium thioacetate (65 mg, 0.57 mmol) was added. The mixture was stirred for 4 h, after which full consumption of starting materials was observed by LCMS. 2 M NaOH (5 mL) was added and the mixture was stirred at rt over the weekend. Water (10 mL) and 1 M HCl (10 mL) were then added. Immediately a yellow precipitate formed, which was collected by extraction with EtOAc (3 x 20 mL). The organic layers were combined, dried over $MgSO_4$, filtered and concentrated under reduced pressure to yield **11a** (60 mg, 0.18 mmol, 74%) a yellow solid, which was used in the next steps without further purification. **TLC** (DCM:MeOH 95:5): R_f = 0.15. **1H NMR** (500 MHz, $(CD_3)_2SO$) δ [ppm] = 12.98 (s, 1H), 7.95 (s, 2H), 7.20 – 7.17 (m, 1H), 7.16 (s, 1H), 7.09 (dd, J = 8.4, 2.1 Hz, 1H), 4.89 (d, J = 2.4 Hz, 2H), 3.80 (s, 4H), 3.62 (t, J = 2.4 Hz, 1H). **^{13}C NMR** (126 MHz, $(CD_3)_2SO$) δ [ppm] = 179.3, 158.4, 154.5, 148.5, 148.2, 127.0, 120.9, 116.8, 114.8, 113.0, 112.3, 102.4, 81.6, 79.0, 78.7, 55.9, 55.8. **LCMS** (ESI, m/z): $[M+H]^+$: 337.00.




2-Amino-6-mercapto-4-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)pyridine-3,5-dicarbonitrile (11b)


Potassium thioacetate (276 mg, 2.42 mmol, 2.0 eq) was added to a solution of **7b** (500 mg, 1.21 mmol, 1.0 eq) in dry DMF (6 mL). The mixture was stirred at rt overnight and the next day another equivalent of potassium thioacetate (138 mg, 1.21 mmol, 1 eq) was added. The mixture was stirred over 3 days, upon which no starting material was visible anymore on TLC. 2 M NaOH (6 mL) was added to hydrolyze the formed thioacetate. After stirring for 8 h at rt, another 6 mL of 2 M NaOH was added and the mixture was stirred overnight. Water (62 mL) and 1 M HCl (24 mL) were added to acidify the mixture. The product was allowed to crystallize overnight. The formed precipitate was collected by filtration, dried under reduced pressure and recrystallized in a mixture of EtOH and MeOH to yield **11b** (253 mg, 0.75 mmol, 62%) as a yellow solid. **TLC** (DCM/MeOH 95:5): R_f = 0.17. **1H NMR** (400 MHz, CD_3OD): δ [ppm] = 7.30 – 7.09 (m, 3H), 4.79 (d, J = 2.5 Hz, 2H), 3.92 (s, 3H), 2.97 (t, J = 2.4 Hz, 1H).

**2-Amino-4-(benzo[d][1,3]dioxol-5-yl)-6-mercaptopyridine-3,5-dicarbonitrile (11c)**

Potassium thioacetate (863 mg, 7.56 mmol, 2.0 eq) was added to **7c** (1409 mg, 3.78 mmol, 1.0 eq) in dry DMF (19 mL). The solution was stirred at rt overnight, after which no starting material was observed anymore by TLC. Therefore 2 M NaOH (20 mL) was added to hydrolyze the formed thioacetate and the mixture was stirred for 7 h. Water (20 mL) was added to quench the and 1 M HCl (40 mL) was slowly added to bring the solution to a pH of 5. Upon addition, a yellow precipitate started to form. Another 80 mL of water was then added and the product was crystallized over 3 days. Afterwards the crystals were collected by filtration and re-crystallized in EtOH and MeOH to yield **11c** (877 mg, 2.96 mmol, 78%) as a yellow solid. **TLC** (DCM/MeOH 95:5): $R_f = 0.23$. **¹H NMR** (400 MHz, CD₃OD): δ [ppm] = 7.12 – 6.89 (m, 3H), 6.07 (s, 2H). **LCMS** (ESI, m/z): $[M+H]^+$: 296.95. **HPLC**: 84%, RT 8.200 min.


**4-((3-((6-Amino-3,5-dicyano-4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)pyridin-2-yl)thio)propyl)carbamoyl)benzenesulfonyl fluoride (2)**

19 (50 mg, 0.15 mmol, 1.4 eq) and NaHCO₃ (19 mg, 0.23 mmol, 1.5 eq) were added to a solution of **11a** in dry DMF (2 mL) and the mixture was stirred overnight. DCM was added and the organic layer was washed with brine (3 x 30 mL), dried over MgSO₄, filtered and concentrated. The residue was purified by silica column chromatography (DCM:MeOH 99.5:0.5 → 95:5) and recrystallization in DCM to yield **2** as a white solid (46 mg, 0.08 mmol, 53% yield). **TLC** (DCM:MeOH 99:1): $R_f = 0.30$. **¹H NMR** (500 MHz, (CD₃)₂SO) δ [ppm] = 8.93 (t, $J = 5.6$ Hz, 1H), 8.26 (d, $J = 8.6$ Hz, 2H), 8.18 (d, $J = 8.5$ Hz, 2H), 7.97 (s, 2H), 7.22 (d, $J = 2.1$ Hz, 1H), 7.18 (d, $J = 8.4$ Hz, 1H), 7.10 (dd, $J = 8.3$, 2.1 Hz, 1H), 4.89 (d, $J = 2.4$ Hz, 2H), 3.81 (s, 3H), 3.62 (t, $J = 2.4$ Hz, 1H), 3.45 (q, $J = 6.5$ Hz, 2H), 3.30 (t, $J = 7.0$ Hz, 2H), 1.97 (p, $J = 6.9$ Hz, 2H). **¹³C NMR** (126 MHz, (CD₃)₂SO) δ [ppm] = 167.0, 164.6, 159.8, 157.9, 148.6, 148.1, 141.5, 133.4 (d, $J = 23.7$ Hz), 129.1, 128.6, 126.8, 121.2, 115.7, 115.5, 113.2, 112.6, 93.7, 85.7, 79.0, 78.7, 55.9, 55.8, 38.5, 28.6, 27.3. **¹⁹F NMR** (471 MHz, (CD₃)₂SO) δ [ppm] = 65.94. **HRMS** (ESI, m/z): $[M+H]^+$, calculated: 580.1117, found: 580.1119. **HPLC**: 95%, RT 10.910 min.

**4-((3-((6-Amino-3,5-dicyano-4-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)pyridin-2-yl)thio)propyl)carbamoyl)benzenesulfonyl fluoride (3)**


NaHCO₃ (43 mg, 0.51 mmol, 1.5 eq) and **19** (150 mg, 0.46 mmol, 1.4 eq) in dry DMF (3 mL) were added to **11b** (115 mg, 0.34 mmol, 1.0 eq) and the mixture was stirred for two days at RT. DCM (20 mL) was then added and the mixture was washed with water (20 mL), dried over

MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (Pentane/EtOAc 1:1 → 1:4) to yield **3** (60 mg, 0.10 mmol, 29%) as an off-white solid. **TLC** (Pentane/EtOAc 7:3): R_f = 0.31. **¹H NMR** (500 MHz, CDCl₃): δ [ppm] = 8.08 – 8.00 (m, 4H), 7.20 – 7.16 (m, 2H), 7.02 (d, *J* = 8.1 Hz, 1H), 6.99 (t, *J* = 6.0 Hz, 1H), 6.04 (s, 2H), 4.80 (d, *J* = 2.4 Hz, 2H), 3.59 (q, *J* = 6.6 Hz, 2H), 3.24 (t, *J* = 7.1 Hz, 2H), 2.59 (t, *J* = 2.4 Hz, 1H), 2.10 (p, *J* = 7.1 Hz, 2H). **¹³C NMR** (126 MHz, CDCl₃): δ [ppm] = 168.6, 165.7, 159.7, 157.6, 152.0, 146.9, 141.0, 135.4 (d, *J* = 25.1 Hz), 128.8, 128.5, 125.3, 123.3, 115.7, 115.6, 114.7, 111.8, 96.1, 86.7, 78.0, 77.0, 57.2, 56.1, 39.6, 28.8, 28.1. **¹⁹F NMR** (471 MHz, CDCl₃): δ [ppm] = 65.72. **HRMS** (ESI, *m/z*): [M+H]⁺, calculated: 580.1119, found: 580.1113. **HPLC**: 96%, RT 10.861 min.




(3-Bromopropoxy)(tert-butyl)dimethylsilane (**13**)

A solution of TBDMS-Cl (50 wt% in toluene) (7.83 mL, 22.50 mmol, 1.5 eq) was added to a solution of 3-bromopropanol (1.36 mL, 15.00 mmol) in dry DMF (10 mL). 1H-imidazole (2.04 g, 30.00 mmol) was added the mixture was stirred for 5 h. DCM (100 mL) was then added and the mixture was washed with water (3 x 100 mL) and brine (1 x 100 mL), dried over MgSO₄ and concentrated under reduced pressure to yield crude **13** (7.60 g, 30.00 mmol, quant). **¹H NMR** (300 MHz, CDCl₃): δ [ppm] = 3.73 (t, *J* = 5.7 Hz, 2H), 3.51 (t, *J* = 6.4 Hz, 2H), 2.04 (p, *J* = 6.5, 6.1 Hz, 2H), 0.89 (s, 9H), 0.06 (s, 6H). **¹³C NMR** (75 MHz, CDCl₃): δ [ppm] = 60.5, 35.7, 30.8, 26.0, 25.8, -5.2.



N-(3-((tert-Butyldimethylsilyl)oxy)propyl)prop-2-yn-1-amine (**14**)


A solution of **13** (3.80 g, 15.00 mmol, 1.0 eq) and DIPEA (5.22 mL, 30.00 mmol, 2.0 eq) in acetonitrile (15 mL) was added dropwise to propargylamine (4.80 mL, 75.00 mmol, 3 eq) over a time period of 5 h using a syringe pump. After 5 h, the mixture had turned orange and LCMS analysis revealed mono- and disubstituted product. EtOAc (200 mL) was added and the mixture was washed with brine (3 x 150 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (Pentane/EtOAc 6:4 → 4:6) to yield **14** (1.78 g, 7.81 mmol, 52%) as a brown oil. **TLC** (EtOAc): R_f = 0.48. **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 3.70 (t, *J* = 6.1 Hz, 2H), 3.42 (d, *J* = 2.4 Hz, 2H), 2.78 (t, *J* = 6.8 Hz, 2H), 2.20 (t, *J* = 2.4 Hz, 1H), 1.71 (p, *J* = 6.4 Hz, 2H), 0.89 (s, 9H), 0.05 (s, 6H). **¹³C NMR** (101 MHz, CDCl₃): δ [ppm] = 82.4, 71.3, 61.9, 46.3, 38.4, 32.8, 28.2, 18.4, -3.3. **LCMS** (ESI, *m/z*): [M+H]⁺: 228.10.



4-((3-((tert-Butyldimethylsilyl)oxy)propyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl fluoride (**15**)


EDC·HCl (1.65 g, 8.59 mmol, 1.1 eq) and **14** (1776 mg, 7.81 mmol, 1.0 eq) in dry DMF (10 mL) were added to a solution of 4-fluorosulfonyl benzoic acid (1.75 g, 8.59 mmol, 1.1 eq) in dry DMF (10 mL) and the mixture was stirred at rt. After stirring for 1 h, DIPEA (2.72 mL, 15.62 mmol, 2.0 eq) was added and the mixture was stirred overnight. The next day additional DIPEA (1.36 mL, 7.81 mmol, 1.0 eq) and **2** (616 mg, 3.02 mmol, 0.4 eq) were added and the mixture was stirred overnight. DIPEA (1.36 mL, 7.81 mmol, 1.0 eq) was added and the mixture was

stirred for another night. As no further progress of the reaction was observed, water (100 mL) was added and the aqueous layer was extracted with DCM (100 mL). The organic layer was washed with water (2 x 100 mL) and the aqueous layers were combined and back-extracted with DCM (100 mL). The organic layers were combined, washed with brine (100 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (Pentane/EtOAc 95:5 → 75:25) to yield yellow oil **15** (1.88 mg, 4.53 mmol, 58%) as a mixture of two rotamers, as determined by ¹H NMR, ¹³C NMR, ¹⁹F NMR and LCMS measurements. **TLC** (Pentane/EtOAc 8:2): R_f = 0.77. **¹H NMR** (500 MHz, CDCl₃): δ [ppm] = 8.08 – 7.92 (m, 2H), 7.66 (dd, *J* = 49.1, 8.0 Hz, 2H), 4.11 (d, *J* = 216.9 Hz, 2H), 3.78 – 3.54 (m, 2H), 3.45 (dt, *J* = 37.9, 6.6 Hz, 2H), 2.31 (d, *J* = 43.6 Hz, 1H), 1.83 (d, *J* = 79.6 Hz, 2H), 0.94 – 0.55 (m, 9H), 0.14 – -0.25 (m, 6H). **¹³C NMR** (126 MHz, CDCl₃): δ [ppm] = 168.8, 168.5, 143.2, 143.1, 133.9, 133.7, 128.7, 128.0, 78.1, 73.6, 72.5, 60.5, 59.6, 46.0, 43.3, 39.5, 34.0, 31.2, 30.8, 30.3, 25.9, 25.7, 25.7, 25.6, -5.4, -5.6. **¹⁹F NMR** (471 MHz, CDCl₃): δ [ppm] = 65.81, 65.71. **LCMS** (ESI, *m/z*): [M+H]⁺: 414.05. **HPLC**: 99%, RT 10.437 min.



4-((3-Hydroxypropyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl fluoride (**16**)


Et₃N·3HF (1.01 mL, 6.18 mmol, 6 eq) was added to a solution of **15** (426 mg, 1.03 mmol, 1.0 eq) in dry THF (5 mL). The mixture was stirred overnight at room temperature, after which DCM (50 mL) was added. The mixture was then washed with brine (2 x 50 mL). The aqueous layers were combined and back-extracted with DCM (50 mL). The organic layers were combined and concentrated under reduced pressure. The residue was purified by flash column chromatography (DCM/MeOH 99.5:0.5 → 98:2) to yield **16** (283 mg, 0.95 mmol, 92%) as a colorless oil. **TLC** (DCM/MeOH 98:2): R_f = 0.38. **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 8.06 (d, *J* = 8.1 Hz, 2H), 7.81 – 7.58 (m, 2H), 3.98 – 3.81 (m, 2H), 3.76 (t, *J* = 6.5 Hz, 2H), 3.65 – 3.47 (m, 2H), 2.51 – 2.27 (m, 1H), 1.87 (p, *J* = 6.1 Hz, 2H). **¹³C NMR** (101 MHz, CDCl₃): δ [ppm] = 169.8, 142.3, 134.3 (d, *J* = 25.0 Hz), 128.9, 128.1, 77.9, 74.2, 58.8, 42.6, 39.5, 29.7. **¹⁹F NMR** (471 MHz, CDCl₃): δ [ppm] = 65.70. **LCMS** (ESI, *m/z*): [M+H]⁺: 299.95. **HPLC**: 100%, RT 8.158 min.



3-(4-(Fluorosulfonyl)-N-(prop-2-yn-1-yl)benzamido)propyl 4-methylbenzenesulfonate (**17**)


TsCl (906 mg, 4.75 mmol, 5.0 eq) and Et₃N (264 μL, 1.90 mmol, 2.0 eq) were added to a solution of **16** (283 mg, 0.95 mmol, 1.0 eq) in dry DMF (5 mL). The mixture was stirred for two days at rt, after which another 2 equivalents of Et₃N (264 μL, 1.90 mmol, 2.0 eq) were added. The mixture was stirred overnight and 2 equivalents of Et₃N (264 μL, 1.90 mmol, 2.0 eq) were added. The mixture was stirred for another 2 h and afterwards diluted with DCM (25 mL). The organic layer was washed with H₂O (25 mL) and brine (25 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (Pentane/Et₂O 7:3 → 3:7) to yield the colorless oil **17** (238 mg, 0.52 mmol, 55%) as a mixture of two rotamers, as determined by ¹H NMR, ¹³C NMR, ¹⁹F NMR and LCMS

measurements. **TLC** (Pentane/EtOAc 1:1): $R_f = 0.46$. **$^1\text{H NMR}$** (500 MHz, CDCl_3): δ [ppm] = 8.17 (d, $J = 8.2$ Hz, 2H), 7.96 (d, $J = 8.5$ Hz, 2H), 7.69 (d, $J = 7.9$ Hz, 2H), 7.11 (d, $J = 7.9$ Hz, 2H), 4.40 (t, $J = 5.9$ Hz, 2H), 4.05 – 3.95 (m, 2H), 3.37 – 3.25 (m, 2H), 2.51 (t, $J = 2.5$ Hz, 1H), 2.46 – 2.41 (m, 2H), 2.30 (s, 3H). **$^{13}\text{C NMR}$** (126 MHz, CDCl_3): δ [ppm] = 164.3, 142.6, 141.1, 136.7 (d, $J = 25.3$ Hz), 136.2, 130.9, 129.1, 128.5, 125.9, 78.1, 73.3, 62.6, 43.7, 36.9, 25.3, 21.4. **$^{19}\text{F NMR}$** (471 MHz, CDCl_3): δ [ppm] = 65.44. **LCMS** (ESI, m/z): $[\text{M}+\text{H}]^+$: 453.95. **HPLC**: 96%, RT 10.945 min. *Only the values of the most abundant rotamer are given.




4-((3-((6-Amino-4-(benzo[d][1,3]dioxol-5-yl)-3,5-dicyanopyridin-2-yl)thio)propyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl fluoride (LUF7909) (4)

11 (238 mg, 0.52 mmol, 1.0 eq) in dry DMF (3 mL) was added to **14** (231 mg, 0.80 mmol, 1.5 eq). NaHCO_3 (44 mg, 0.52 mmol, 1.0 eq) was added and the mixture was stirred overnight at rt. The mixture was then diluted with DCM (25 mL). The organic layer was washed with brine (4 x 25 mL), dried over MgSO_4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (Pentane/Et₂O 4:6 $\rightarrow$ 1:9) to yield **3** (90 mg, 0.16 mmol, 31%) as an off-white solid. **TLC** (Pentane/EtOAc 1:1): $R_f = 0.47$. **$^1\text{H NMR}$** (500 MHz, CDCl_3 , 20 °C): δ [ppm] = 8.09 (d, $J = 7.8$ Hz, 2H), 7.87 – 7.61 (m, 2H), 7.00 (dd, $J = 8.0$, 1.7 Hz, 1H), 6.95 (d, $J = 1.7$ Hz, 1H), 6.93 (d, $J = 8.0$ Hz, 1H), 6.28 – 5.82 (m, 4H), 4.20 (d, $J = 256.2$ Hz, 2H), 3.68 (d, $J = 99.6$ Hz, 2H), 3.12 (d, $J = 114.7$ Hz, 2H), 2.54 – 2.31 (m, 1H), 2.31 – 2.13 (m, 2H). **$^1\text{H NMR}$** (500 MHz, CDCl_3 , 59 °C): δ [ppm] = 8.08 (d, $J = 7.9$ Hz, 2H), 7.74 (d, $J = 7.8$ Hz, 2H), 7.00 (dd, $J = 8.0$, 1.8 Hz, 1H), 6.96 (d, $J = 1.8$ Hz, 1H), 6.93 (d, $J = 8.0$ Hz, 1H), 6.05 (s, 2H), 5.93 (s, 2H), 4.01 (s, 2H), 3.73 (s, 2H), 3.20 (s, 2H), 2.45 – 2.27 (m, 1H), 2.27 – 1.92 (m, 2H). **$^{13}\text{C NMR}$** (126 MHz, CDCl_3): δ [ppm] = 169.1, 168.7, 159.7, 157.8, 150.0, 148.3, 142.5, 134.5 (d, $J = 25.7$ Hz), 129.1, 128.1, 126.8, 123.3, 115.6, 115.2, 109.0, 108.9, 102.0, 96.4, 86.7, 78.0, 74.4, 45.9, 40.1, 28.3, 27.0. **$^{19}\text{F NMR}$** (471 MHz, CDCl_3): δ [ppm] = 65.78. **HRMS** (ESI, m/z): $[\text{M}+\text{H}]^+$, calculated: 578.0963, found: 578.1054. **HPLC**: 96%, RT 11.122 min.



4-(Fluorosulfonyl)benzoic acid (18)

A solution of potassium bifluoride (2.34 g, 30.0 mmol, 3 eq) in water (20 mL) (1.5 M) was added to a solution of 4-(chlorosulfonyl)benzoic acid (2.21 g, 10.0 mmol, 1 eq) in dioxane (25 mL). The mixture was stirred for 3 h, after which TLC and LCMS showed full consumption of starting material. EtOAc (120 mL) was added and the organic layer was washed with water (2 x 150 mL) and brine (1 x 100 mL). The aqueous layers were combined and back-extracted with EtOAc (100 mL). The organic layers were collected, dried over MgSO_4 , filtered and concentrated under reduced pressure to yield **18** (1.93 g, 9.47 mmol, 95%) as a white solid. **TLC** (PE/EtOAc 3:2 + 1% AcOH): $R_f = 0.34$. **$^1\text{H-NMR}$** (500 MHz, CD_3OD): δ [ppm] = 8.33 (d, $J = 7.9$ Hz, 2H), 8.18 (d, $J = 8.3$ Hz, 2H). **$^{19}\text{F NMR}$** (471 MHz, CD_3OD): δ [ppm] = 63.37.



4-((3-Bromopropyl)carbamoyl)benzenesulfonyl fluoride (**19**)

3-bromopropylamine hydrobromide (2.18 g, 10.0 mmol, 1.3 eq) and PyBrop (4.26 g, 9.1 mmol, 1.2 eq) were added to a solution of **18** (1.55 g, 7.6 mmol, 1 eq) in anhydrous DMF (1 mL) under N₂. DiPEA (2.7 mL, 15.0 mmol, 2 eq) was added dropwise and the mixture was stirred at room temperature. After 3 days of stirring, TLC indicated starting material to be still present. Therefore an additional 0.6 eq of PyBrop (2.13 g, 4.6 mmol) and 1 eq of DiPEA (1.3 mL, 7.6 mmol) were added and the mixture was stirred for another 9 days at rt. The mixture was then diluted with EtOAc (350 mL) and the organic layer was washed brine (350 mL) and water (2 x 350 mL), dried over MgSO₄, filtrated and concentrated under reduced pressure. The residue was purified by flash column chromatography (PE/EtOAc 2:1) to yield **19** (1.00 g, 3.1 mmol, 41%) as a white solid. **TLC** (PE/EtOAc 2:1): R_f = 0.57. **¹H NMR** (400 MHz, CDCl₃): δ [ppm] = 8.10 (d, *J* = 8.5 Hz, 2H), 8.01 (d, *J* = 8.0 Hz, 2H), 6.45 (s, 1H), 3.68 (q, *J* = 6.5 Hz, 2H), 3.51 (t, *J* = 6.3 Hz, 2H), 2.25 (p, *J* = 6.5 Hz, 2H). **¹⁹F NMR** (471 MHz, CDCl₃): δ [ppm] = 65.75.

Biology

Cell lines

Chinese hamster ovary (CHO) cells stably expressing the human adenosine A₁ receptor (CHOhA₁AR) were kindly provided by Prof. S.J. Hill (University of Nottingham, UK). Human embryonic kidney 293 cells stably expressing the human adenosine A_{2A} receptor (HEK293hA_{2A}AR) were kindly provided by Dr. J. Wang (Biogen/IDEC, Cambridge, MA). CHO-spap cells stably expressing the wildtype (WT) hA_{2B} receptor (CHO-spap-hA_{2B}AR) were kindly provided by S.J. Dowell (Glaxo Smith Kline, UK). CHO cells stably expressing the human adenosine A₃ receptor (CHOhA₃AR) were a kindly provided by Dr. K.N. Klotz (University of Würzburg, Germany).

Radioligands

[³H]1,3-diethyl-8-cyclopentyl-xanthine ([³H]DPCPX, specific activity 137 Ci/mmol) and [³H]4-(-2-[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl) phenol ([³H]-ZM241385, specific activity 50 Ci/mmol) were purchased from ARC Inc. (St. Louis, USA). [³H]8-(4-(4-(4-Chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine ([³H]PSB-603, specific activity 79 Ci/mmol) was purchased from Quotient Bioresearch. [³H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-*i*]-purin-5-one ([³H]PSB-11, specific activity 56 Ci/mmol) was obtained with the kind help of Prof. C.E. Müller (University of Bonn, Germany). [³⁵S]-guanosine 5'-(γ-thio)triphosphate ([³⁵S]GTPγS, specific activity 1250 Ci/mmol) was purchased from PerkinElmer.

Chemicals

5'-N-ethylcarboxamidoadenosine (NECA), N6-Cyclopentyladenosine (CPA) and adenosine deaminase (ADA) were purchased from Sigma Aldrich. 4-(-2-[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl) phenol (ZM241385) was a gift from Dr. S.M. Poucher (Astra Zeneca, Manchester, UK). 3-[4-[2-[[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl] propanoic acid (CGS21680) was purchased from Ascent Scientific (Bristol, UK). Bongkreic acid was obtained from Enzo Life Sciences (cat # BML-CM113). Protease inhibitor cocktail was purchased from Sigma Aldrich (cat # p8340). Bicinchoninic acid (BCA) protein assay reagents were obtained

from Pierce Chemical Company (Rockford, IL, USA).^[61] AF647-N₃ was obtained from Jena Bioscience, Azide-Fluor-545 and Biotin-PEG3-Azide were ordered from Sigma Aldrich. Pierce™ Avidin agarose beads (cat # 11846734) and Pierce™ ECL Western Blotting Substrate (cat # 32209) were ordered from Thermo Scientific. All other chemicals were of analytical grade and obtained from standard commercial sources.

Biologicals

Collagenase type I was purchased from Sigma Aldrich (Cat # C0130), PNGase was purchased from Promega (cat # V4831), Chymotrypsin was ordered from Promega (cat # V1062) and Enolase digest was ordered from Waters (cat # 186002325). RabbitaraA₁AR antibody was ordered from Sigma Aldrich (cat # A268) and goatrabbit-HRP antibody was purchased from Jackson ImmunoResearch Laboratories (cat # 115-035-003). Bovine Serum Albumin (BSA) was purchased from Acros Organics (cat # 268131000).

Fat pads

Gonadal fat pads from female mice were kindly donated by prof. Patrick C.M. Rensen and dr. Milena Schönke and obtained from APOE*3-Leiden.CETP mice (C57Bl/6J background). Mice were between 28 and 34 weeks old and 19.9-25.3 g at the time of sacrifice. All mouse experiments were performed in accordance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals after approval from the Central Animal Experiments Committee ("Centrale Commissie Dierproeven").

Cell culture and membrane preparation

CHO cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F12 medium (1:1) supplemented with 10% (v/v) newborn calf serum 50 µg/mL streptomycin, 50 IU/mL penicillin and 5% CO₂. CHO cells were subcultured twice a week at a ratio of 1:15 on 10 cm Ø plates. CHO_{hA₁AR} and CHO_{hA₃AR} cells were grown in DMEM and Ham's F12 medium (1:1) supplemented with 10% (v/v) newborn calf serum, 50 µg/mL streptomycin, 50 IU/mL penicillin, and 200 µg/mL G418 at 37 °C and 5% CO₂. CHO_{hA₁AR} cells were subcultured twice a week at a ratio of 1:20 on 10 cm Ø plates. CHO_{hA₃AR} cells were subcultured twice a week at a ratio of 1:8 on 10 cm Ø plates. HEK293_{hA_{2A}AR} cells were grown in culture medium consisting of DMEM supplemented with 10% newborn calf serum, 50 µg/mL streptomycin, 50 IU/mL penicillin, and 500 µg/mL G418 at 37 °C and 7% CO₂. Cells were subcultured twice a week at a ratio of 1:8 on 10 cm Ø plates. CHO-spap-hA_{2BR} cells were grown in DMEM and Ham's F12 medium (1:1) supplemented with 10% (v/v) newborn calf serum, 100 µg/mL streptomycin, 100 IU/mL penicillin, 1 mg/mL G418, and 0.4 mg/mL hygromycin at 37 °C and 5% CO₂. Cells were subcultured twice a week at a ratio of 1:20 on 10 cm Ø plates.

All cells were grown to 80-90% confluency and detached from plates by scraping them into 5 mL PBS. Detached cells were collected and centrifuged (5 min, 200 G). The supernatant was removed and the pellets were resuspended in cold Tris-HCl buffer, pH 7.4. A Heidolph D1ax 900 homogenizer was used to homogenize the cell suspension. Membranes and the cytosolic fraction were separated by centrifugation in a Beckman Optima LE-80 K ultracentrifuge (Beckman Coulter, Fullerton, CA) (20 min, 100 000 G, 4 °C). The pellet was resuspended in Tris-HCl buffer, and homogenization and centrifugation steps were repeated. Tris-HCl buffer was used to resuspend the pellet, and ADA was added (0.8 U/mL) to break down endogenous adenosine. Membranes were stored in 250 µL and 500 µL aliquots at -80 °C. Total protein concentrations were measured using the BCA method.

Preparation of adipocyte membranes from mouse gonadal fat pads^[58,62,63]

Gonadal fat pads of 6 mice were placed into a 10 Ø petri dish containing Krebs-Ringer-HEPES (KRH) buffer (100 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 3.6 mM NaHCO₃, 1.19 mM MgSO₄, 1.18 mM KH₂PO₄, 5 mM dextrose, 5 mM pyruvic acid, 1 mM ascorbic acid and 5 mM HEPES (pH 7.4) containing 1% fatty acid free BSA (Tebu-Bio). The fat pads were minced with scissors, added to a 50 mL centrifuge tube and KRH buffer was added to a final volume of 46 mL. 50 mg Collagenase type I and 2 µM nicotinic acid in 4 mL KRH buffer were added and the mixture was digested for 1 h at 37 °C.^[64] The resulting mixture was poured through a 200 µm cell strainer (pluriSelect Life Science) that was put onto a new 50 mL centrifuge tube. The filtrate was centrifuged (1 min, 400 G) and subsequently left for 5 min, upon which the adipocytes floated on top of the solution. The infranant was removed and the adipocyte layer (±5 mL) was washed by addition of 45 mL KRH buffer and repetition of the centrifugation and floatation steps. The remaining 5 mL of adipocytes was dissolved in 45 mL of homogenization buffer (0.25 M sucrose, 1 mM EDTA and 10 mM Tris-HCl (pH 7.4)), put on ice and homogenized by 20 up-and-down strokes of a motor-driven pestle (700 rpm). The homogenate was kept cold and centrifuged (30 min, 15 000 G, 4 °C). The upper fat layer (45 mL) was transferred to a new 50 mL centrifuge tube, homogenization buffer (5 mL) was added and the homogenization steps were repeated twice, yielding three supernatant fractions in total. The supernatant fractions were combined and centrifuged (30 min, 15 000 G, 4 °C) to pellet the membranes. The supernatant was removed and the pellet was redissolved in assay buffer (50 mM Tris-HCl, pH 7.4). Adipocyte membranes from mice typically contain about 0.5-2 pmol of adenosine A₁ receptor per mg of membrane protein.^[58]

Radioligand displacement assays

Single point radioligand displacement experiments were performed using 1 µM of competing ligand, full curve radioligand displacement experiments were performed using a concentration range of competing ligand, ranging from 10⁻¹¹ to 10⁻⁶ M. Experiments were carried out using 1.6 nM [³H]DPCPX for CHOhA₁AR, 5.5 nM [³H]ZM241385 for HEK293hA_{2A}AR, 1.5 nM [³H]PSB-603 for CHO-spap-hA_{2B}AR, and 10 nM [³H]PSB11 for CHOhA₃AR. Nonspecific binding was determined in the presence of 100 µM CPA for CHOhA₁AR, 100 µM NECA for HEK293hA_{2A}AR and CHOhA₃AR, and 10 µM ZM241385 for CHO-spap-hA_{2B}AR. Competing ligand (50 µL) and radioligand (50 µL) were co-incubated with membrane aliquots containing the respective receptor. Membrane aliquots containing 5 µg (CHOhA₁AR) total protein were incubated in a total volume of 100 µL assay buffer (50 mM Tris-HCl, pH 7.4) at 25 °C for 1 h. Membrane aliquots containing 30 µg (HEK293hA_{2A}AR) total protein were incubated in a total volume of 100 µL assay buffer (50 mM Tris-HCl, pH 7.4) at 25 °C for 1 h. Membrane aliquots containing 30 µg (CHO-spap-hA_{2B}AR) total protein were incubated in a total volume of 100 µL assay buffer (0.1% CHAPS in 50 mM Tris-HCl, pH 7.4) at 25 °C for 2 h. Membrane aliquots containing 15 µg (CHOhA₃AR) total protein were incubated in a total volume of 100 µL assay buffer (50 mM Tris-HCl, 10 mM MgCl₂, 1mM EDTA, 0.01% (w/v) CHAPS, pH 8.0) at 25 °C for 2 h. During full curve displacement experiments, CHOhA₁AR membranes and competing ligand were pre-incubated for either 0 or 4 h at 25 °C, prior to addition of radioligand and subsequent co-incubation. Incubations were terminated by rapid vacuum filtration to separate the bound and free radioligand through prewetted 96-well GF/B filter plates using a PerkinElmer Filtermate-harvester (PerkinElmer). Filters were subsequently washed 12 times with ice-cold wash buffer: 50 mM Tris-HCl, pH 7.4 for CHOhA₁AR and HEK293hA_{2A}AR; 0.1% BSA in 50 mM Tris-HCl, pH 7.4 for CHO-spap-hA_{2B}AR; and 50 mM Tris-HCl, 10 mM MgCl₂, 1mM EDTA, pH 8.0 for CHOhA₃AR. The plates were dried at 55 °C after which MicroscintTM-20 cocktail was added (PerkinElmer). After 3 h the filter-bound radioactivity was determined by scintillation spectrometry using a 2450 MicroBeta Microplate Counter (PerkinElmer).

Wash-out assay

Wash-out assays were performed as previously described, using 100 µg of protein in 100 µL cell membrane suspension.^[16]

Functional [³⁵S]GTPγS binding assay

[³⁵S]GTPγS binding assays were performed as previously described, using CHO cells that were stably transfected with the A₁AR.^[16]

Data Analysis

All experimental data were analyzed using the non-linear regression curve fitting program GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA). IC₅₀ values obtained from competition displacement binding data were converted into K_i values using the Cheng-Prusoff equation.^[65] The K_D value of [³H]DPCPX (1.6 nM) at CHOhA₁AR membranes was taken from Kourounakis *et al.*^[66] The K_D value (1.0 nM) of [³H]ZM241385 at hA_{2A}AR membranes, the K_D value (1.7 nM) of [³H]PSB603 at CHO-spap-hA_{2B}AR membranes, and the K_D value (17.3 nM) of [³H]PSB11 at CHOhA₃AR membranes were taken from in-house determinations.

SDS-PAGE experiments of LUF7909 in membrane fractions

18 µL of membrane fractions (1 mg/mL) were pre-incubated with 1 µL competing ligand (final concentration: 1 µM, unless stated otherwise) or DMSO (1%) for 1 h (rt, 650 rpm). 1 µL of LUF7909 was added (final concentration: 100 nM, unless stated otherwise) and the membranes were incubated for 1 h (rt, 650 rpm). 1 µL PNGase (10u) or MilliQ water was added and the membranes were incubated for 1 h (rt, 650 rpm). Click mix was prepared freshly by mixing 50 µL 100 mM CuSO₄, 30 µL 1 M sodium ascorbate (NaAsc), 10 µL 100 mM tris(3-hydroxypropyl)triazolylmethylamine (THPTA) and 10 µL 100 µM AF647-N₃. 2.3 µL of click mix was added and the membranes were shaken for 1 h (rt, 650 rpm). 7.8 µL of 4 x Laemmli Sample Buffer (Bio-Rad) containing β-mercaptoethanol was added and the membranes were shaken for 2 h (rt, 650 rpm). The samples were then subjected to 12.5% SDS-PAGE (180 V, 100 min). In-gel fluorescence was measured on a Bio-Rad Universal Hood III using Cy3 (605/50 filter) or Cy5 (695/55 filter) settings. Gels were transferred to 0.2 µm PVDF blots using a Trans-Blot Turbo Transfer System (Bio-Rad)(2.5 A, 7 min) or stained with Coomassie Brilliant Blue. Gel images were analyzed with Image Lab software (Bio-Rad).

SDS-PAGE experiments of LUF7909 in live CHOhA₁AR and CHO cells

CHOhA₁AR or CHO medium (as described above) containing 1 µM DPCPX or 1% DMSO (control) was added to a 10 cm Ø plate containing the respective cells (~90% confluence). The cells were incubated for 1 h (37 °C, 5% CO₂). The medium was removed, replaced by medium containing 100 nM LUF7909 or 1% DMSO (control) and the cells were incubated for 1 h (37 °C, 5% CO₂). The cells were washed with PBS and membranes were collected (as described above). Membrane pellets were diluted to 1 mg/mL and 20 µL was taken per sample. Click mix was prepared freshly by mixing 50 µL 100 mM CuSO₄, 30 µL 1 M NaAsc, 10 µL 100 mM THPTA and 10 µL 100 µM AF647-N₃. 2.2 µL of click mix was added and the membranes were shaken for 1 h (rt, 650 rpm). 7.4 µL of 4 x Laemmli Sample Buffer containing β-mercaptoethanol was added and the membranes were shaken for 2 h (rt, 650 rpm). The samples were then subjected to 12.5% SDS-PAGE (180 V, 100 min) and in-gel fluorescence was measured on a Bio-Rad Universal Hood III. Gels were transferred to 0.2 µm PVDF blots using a Trans-Blot Turbo Transfer System (Bio-Rad)(2.5 A, 7 min) or stained with Coomassie Brilliant Blue. Gel images were analyzed with Image Lab software (Bio-Rad).

Western Blot experiments

Blots were blocked in 5% BSA in TBST (1 h, rt), prior to incubation with primary antibody: rabbit α ratA₁AR (Sigma Aldrich, cat # A268) 1:5000 in 1% BSA in TBST (overnight, 4 °C). The blots were washed (3 x TBST) and incubated with secondary antibody: goat α rabbit-HRP (Jackson ImmunoResearch Laboratories, cat # 111-035-003) 1:2000 in 1% BSA in TBST. The blots were washed (2 x TBST, 1 x TBS), incubated with 1 mL of luminol enhancer solution and 1 mL of peroxide solution (PierceTM, ThermoFisher cat # 32106)(3 min, rt, dark) and scanned using chemiluminescence and fluorescence. Blot images were analyzed with Image Lab software (Bio-Rad).

Affinity-based pull-down proteomics^[67]

Probe Incubation

A. CHO α A₁AR and CHO membranes

CHO α A₁AR or CHO membrane fractions were resuspended in assay buffer (50 mM Tris-HCl, pH 7.4) and diluted to a concentration of 2 mg/mL. 25 μ L of LUF7746 (final concentration: 10 μ M), 10% SDS or 1% DMSO in assay buffer was added to 200 μ L of membranes and the membranes were incubated for 1 h (rt, 650 rpm). 25 μ L of LUF7909 (final concentration: 1 μ M) or 1% DMSO in assay buffer was added and the membranes were incubated for 2 h (rt, 650 rpm).

B. Live CHO α A₁AR cells

CHO α A₁AR medium (as described above) containing 1 μ M LUF7909 or 1% DMSO (control) was added to a 10 cm $\varnothing$ plate containing CHO α A₁AR cells (~90% confluence). The cells were incubated for 2 h (37 °C, 5% CO₂). The medium was removed, the cells were washed with PBS and membranes were collected (as described above). Membrane pellets were diluted to 2 mg/mL, 225 μ L was taken per sample and 25 μ L of 1% DMSO in assay buffer (50 mM Tris-HCl, pH 7.4) was added.

Click reaction, precipitation, reduction and alkylation

Click mix was prepared freshly by mixing 350 μ L 100 mM CuSO₄, 210 μ L 1 M NaAsc, 70 μ L 100 mM THPTA and 70 μ L 1 mM Biotin-PEG3-Azide. 27.5 μ L of click mix was added per sample (from A or B) and the samples were incubated for 1 h (rt, 650 rpm). 92.5 μ L 10% SDS (final SDS concentration: 2.5%) was added and the proteins were denatured for 1 h (rt, 650 rpm). Proteins were precipitated based on the method of Wessel and Flügge.^[68] In brief, 800 μ L MeOH, 400 μ L CHCl₃ and 400 μ L water were added and the proteins were pelleted by centrifugation (10 min, 1 500 G, rt). The upper (aqueous) layer was removed and 600 μ L MeOH was added. The samples were centrifuged a second time (10 min, 1 500 G, rt) and supernatant was removed to yield a more purified protein fraction. The proteins were then resuspended in 500 μ L 1% SDS containing 25 mM NH₄HCO₃. Probe sonication (Sonics Vibra-Cell, 3 x 5 s, 30% amplitude) was necessary to fully dissolve the membrane proteins. The proteins were reduced by addition of 10 μ L 0.5 M dithiothreitol (DTT) (15 min, 65 °C, 700 rpm), alkylated by addition of 80 μ L 0.25 M iodoacetamide (IAA) (30 min, rt, dark) and further reduced by addition of 10 μ L 0.5 M DTT (15 min, rt, 700 rpm).

Pull-down

1400 μL of Avidin Agarose beads was divided over two 15 mL centrifuge tubes, washed with PBS (4 mL) and centrifuged (2 min, 2 500 G, rt). The supernatant was removed and the washing steps were repeated twice. The washed beads were resuspended in 2.3 mL PBS. 250 μL of the beads solution was added per protein-containing sample and the mixture was added to a 15 mL centrifuge tube containing 9.1 mL PBS (final SDS concentration: 0.05%). The tubes were incubated overnight while rotating at 4 °C. The next day, beads were pelleted (200 G, 2 min, rt), supernatant was removed and the beads were transferred to a 2 mL Eppendorf tube. The beads were washed subsequently with 1 mL 0.1% SDS in PBS, 1 mL PBS (3 x) and 1 mL on-bead digestion buffer (100 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM CaCl_2 and 2% (v/v) acetonitrile),^[67] samples were centrifuged (2 min, 2 500 G, rt) after each step and supernatant fractions were removed.

Digestion and desalting

The remaining beads were dissolved in 250 μL on-bead digestion buffer. 2 μL chymotrypsin (0.5 $\mu\text{g}/\mu\text{L}$ in 1 mM HCl) (cat # V1062, Promega) was added and the proteins were digested overnight (1000 rpm, 37 °C). The samples were quenched by addition of 12.5 μL of formic acid and beads were removed by centrifugation with Bio-spin columns (Bio-Rad) (2 min, 600 G, rt). Samples were purified using StageTips, as reported by Rappsilber *et al.* and van Rooden *et al.*^[67,69] Briefly, StageTips were pre-conditioned with 50 μL MeOH, 50 μL of 0.5% (v/v) formic acid in $\text{H}_2\text{O}:\text{MeCN}$ 2:8 and 50 μL of 0.5% (v/v) formic acid in H_2O . Peptide samples were then loaded on the StageTips and washed by addition of 100 μL of 0.5% (v/v) formic acid in H_2O and centrifugation (2 min, 600 G, rt). Peptides were eluted in low-binding Eppendorf tubes by addition of 0.5% (v/v) $\text{H}_2\text{O}:\text{MeCN}$ 8:2 to the StageTips and subsequent centrifugation (2 min, 600 G, rt). The solvents were evaporated in an Eppendorf Concentrator Plus (60 °C).

Nano-LC-MS Settings

Desalted peptide samples were reconstituted in 50 μL 97:3:0.1 solution (H_2O , MeCN, FA) containing 10 fmol/ μL yeast enolase digest. The desalted peptides solution was separated on an UltiMate 3000 RSLCnano system set in a trap-elute configuration with a nanoEase M/Z Symmetry C18 100Å, 5 μm , 180 μm x 20 mm (Waters) trap column for peptide loading/retention and nanoEase M/Z HSS C18 T3 100Å, 1.8 μm , 75 μm x 250 mm (Waters) analytical column for peptide separation. The column was kept at 40°C in a column oven. Samples were injected on the trap column at a flow rate of 15 $\mu\text{L}/\text{min}$ for 2 min with 99%A, 1%B eluent. The 85 min LC method, using mobile phase A (0.1% formic acid (FA) in ULC-MS grade water (Biosolve)) and mobile phase B (0.1% FA in ULC-MS grade acetonitrile (MeCN, Biosolve)) controlled by a flow sensor at 0.3 $\mu\text{L}/\text{min}$ with average pressure of 400-500 bar (5500-7000 psi), was programmed as gradient with linear increment to 1% B from t_0 to t_2 min, 5%B at t_5 min, 22%B at t_{55} , 40%B at t_{64} , 90%B at t_{65} to t_{74} and 1%B at t_{75} to t_{85} min. The eluent was introduced by electrospray ionization (ESI) via the nanoESI source (Thermo) using stainless steel Nano-bore emitters (40 mm, OD 1/32", ES542, Thermo Scientific). The QExactive HF was operated in positive mode with data dependent acquisition without the use of lock mass, default charge of 2+ and external calibration with LTQ Velos ESI positive ion calibration solution (88323, Pierce, Thermo) every 5 days to less than 2 ppm. The tune file for the survey scan was set to scan range of 350 – 1400 m/z , 60,000 resolution (m/z 200), 1 microscan, automatic gain control (AGC) of 1e6, max injection time of 50 ms, no sheath, aux or sweep gas, spray voltage ranging from 1.7 to 3.0 kV, capillary temp of 250°C and an S-lens value of 80. For the 10 data dependent MS/MS events the loop count was set to 10 and the general settings were resolution to 15,000, AGC target 1e5, max IT time 100 ms, isolation window of 1.6 m/z , no fixed first mass and normalized collision energy (NCE) of 28 eV. For individual peaks the data dependent

settings were 5.00e4 for the minimum AGC target yielding an intensity threshold of 5.0e5 that needs to be reached prior of triggering an MS/MS event. No apex trigger was used, unassigned, +1 and charges >+8 were excluded with peptide match mode preferred, isotope exclusion on and dynamic exclusion of 20 sec. In between experiments, routine wash and control runs were done by injecting 5 µl 97.3.0.1 solution, 5 µl of 10 fmol/µl BSA or enolase digest and 1 µl of 10 fmol/µl angiotensin III (Fluka, Thermo)/oxytocin (Merck) to check the performance of the platform on each component (nano-LC, the mass spectrometer (mass calibration/quality of ion selection and fragmentation) and the search engine).

LC-MS/MS Data processing

MaxQuant (version 1.6.17.0)^[70] was used for peptide identification and quantification using a custom made fasta file consisting of the Chinese Hamster proteome from the Uniprot database (UPID: UP000001075, downloaded January 12, 2021), the BETAS background (BSA P02769, yeast enolase P00924, trypsin pig P00761, avidin P02701 and streptavidin P22629) and the adenosine A₁ receptor plus its isoform (P30542-1 and P30542-2). The following changes and additions were made to the standard settings of MaxQuant: The digestion enzyme was set to Chymotrypsin+ with 2 max. missed cleavages. Label-free quantification was chosen with an LFQ min. ratio count of 2. "Match between runs" was enabled. The minimum amount of peptides for protein identification was set to 3. The peptide length was set to be between 7 and 25 with a max. peptide mass of 4600 Da. Oxidation (M) was set as possible peptide modifications and Carbamidomethyl (C) was set as fixed peptide modification. Contaminants were included. An FDR of 0.01 was used for PSM FDR, Protein FDR and Site decoy FDR. Six technical replicates of four different conditions were analyzed in the same MaxQuant analysis. The "peptides.txt" and "proteingroups.txt" files were used for further analysis. Proteins labelled as contaminant were removed from the output files. The LFQ intensities of major proteins were further analyzed in GraphPad Prism 8.1.1. for Windows (GraphPad Software Inc., San Diego, CA). Values of six technical replicates were used per condition. The log₂(ratio) and p-values were determined by standard Volcano Plot settings, using multiple t-tests to calculate the p-values. Log₂(ratio) values show the ratio between the probe positive samples (+1 µM LUF7909) and the control samples (DMSO, or pre-incubation with 1%SDS or 10 µM LUF7746).

Click microscopy experiments using LUF7909 in CHO_hA₁AR and CHO cells^[71]

CHO_hA₁AR and CHO cells were seeded in 96-wells plates and grown overnight in their respective medium (as described above). The next day, medium was replaced by medium containing 1 µM of DPCPX, 1 µM of FSCPX or 1% DMSO (control) and the cells were incubated for 1 h (37 °C, 5% CO₂). The medium was then replaced by medium containing 100 nM LUF7909 or 1% DMSO (control) and the cells were incubated for 1 h (37 °C, 5% CO₂). Excess probe was washed away with PBS and the cells were fixed by incubation with a solution of 4% PFA in 10% formalin for 10 min. The remaining fixative was washed away with PBS and 20 mM glycine in PBS and subsequently the cells were permeabilized by a 10 min incubation with 0.1% saponin in PBS. Remaining saponin was washed away with PBS and the fixed cells were stored at 4 °C until further steps were taken. Click mix was prepared freshly by mixing 100 µL 100 mM CuSO₄, 100 µL 1 M NaAsc, 100 µL 100 mM THPTA, 9.66 mL HEPES buffer (pH = 7.4) and 40 µL 1 mM Azide-Fluor-545. 100 µL of click mix was added per well and the fixed cells were incubated for 1 h (rt, dark). Remaining click mix was washed away with PBS and by incubation for 30 min with 1% BSA in PBS. The fixed cells were stored in PBS containing 300 nM DAPI until imaging by confocal microscopy.

Image acquisition

Microscopy was performed on a Nikon Eclipse Ti2 C2+confocal microscope (Nikon, Amsterdam, The Netherlands) and this system included an automated xy-stage, an integrated Perfect Focus System (PFS) and 408 and 561 lasers. The system was controlled by Nikon's NIS software. All images were acquired using a 20x objective with 0.7 NA, at a resolution of 1024×1024 pixels for the main figure and 512×512 pixels for the SI figure. The acquisition of 9 fields of view per well was done automatically using the NIS Jobs functionality. Representative images are shown in the figure and created by using OMERO.^[57]

Quantification of the Tamra-N₃ signal at single cell level

CellProfiler (version 2.2.0) was used to create a binary image of the Dapi channel and to propagate the cytoplasmic area based on the Dapi binary. An overlay of the binary cytoplasm/Tamra-N₃ channel was generated to quantify per segmented pixel the Tamra-N₃ intensity. The sum of these intensities in the cytoplasm mask is referred to as the integrated Tamra-N₃ intensity in the cytoplasm. Segmentation results were further processed using Excel while GraphPadPrism 9 was used for data visualization and statistics.

Computational Procedures

Covalent Docking of LUF7909 in the adenosine A₁ receptor

All calculations were performed in the Schrödinger Suite (release 2019-1) using the standard settings in Maestro (version 11.9).^[59] The crystal structure of adenosine-bound human A₁AR (PDB: 6D9H) was used for docking LUF7909. The protein and ligand were prepared for docking using the protein preparation tool and LigPrep tool, respectively. Adenosine was removed and induced fit docking was performed to dock LUF7909. Docking poses were compared to the binding pose of LUF5833 in the human A_{2A}AR (PDB: 7ARO) using the superposition tool. The pose with the lowest scoring RMSD was further used in covalent docking calculations.^[60] A custom reaction type was made to allow nucleophilic substitution of the phenolic OH onto the fluorosulfonyl group. This contained the following lines of code:

```
RECEPTOR_SMARTS_PATTERN 2,[c;r6]-[S,O;H1,-1]
RECEPTOR_SMARTS_PATTERN 2,[C]-[N;H2,H3]
LIGAND_SMARTS_PATTERN 1,[*][F,Cl,Br,I]
CUSTOM_CHEMISTRY ("<1>","charge",0,(1))
CUSTOM_CHEMISTRY ("<1>|<2>","bond",1,(1,2))
CUSTOM_CHEMISTRY ("<2>[F,Cl,Br,I]","delete",2))
```

The covalent binding poses of LUF7909 were compared to the binding pose of LUF5833 in the human A_{2A}AR using the superposition tool, as well as evaluated by visual inspection.

Author Contributions

B.L.H.B. and C.K. synthesized compounds. R.L. performed radioligand displacement experiments. B.L.H.B. performed SDS-PAGE experiments. B.L.H.B. performed molecular docking experiments. B.L.H.B. and B.I.F. performed MS-based pull-down experiments and carried out MS data analysis. B.L.H.B. and S.L.D. performed confocal microscopy experiments. S.L.D. carried out confocal microscopy data analysis. L.H.H., A.P.I.J. and D.v.d.E. supervised the project.

References

- [1] B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden, C. E. Müller, *Pharmacol Rev* 2011, 63, 1–34.
- [2] A. P. IJzerman, K. A. Jacobson, C. E. Müller, B. N. Cronstein, R. A. Cunha, *Pharmacol Rev* 2022, 74, 340–372.
- [3] B. Allard, D. Allard, L. Buisseret, J. Stagg, *Nat Rev Clin Oncol* 2020, 17, 611–629.
- [4] C. J. Draper-Joyce, R. Bhola, J. Wang, A. Bhattarai, A. T. N. Nguyen, I. Cowie-Kent, K. O'Sullivan, L. Y. Chia, H. Venugopal, C. Valant, D. M. Thal, D. Wootten, N. Panel, J. Carlsson, M. J. Christie, P. J. White, P. Scammells, L. T. May, P. M. Sexton, R. Danev, Y. Miao, A. Glukhova, W. L. Imlach, A. Christopoulos, *Nature* 2021, 597, 571–576.
- [5] C. E. Müller, K. A. Jacobson, *Biochim Biophys Acta* 2011, 1808, 1290–1308.
- [6] J. F. Chen, H. K. Eltzschig, B. B. Fredholm, *Nat Rev Drug Discov* 2013, 12, 265–286.
- [7] Y. Yun, J. Chen, R. Liu, W. Chen, C. Liu, R. Wang, Z. Hou, Z. Yu, Y. Sun, A. P. IJzerman, L. H. Heitman, X. Yin, D. Guo, *Biochem Pharmacol* 2019, 164, 45–52.
- [8] D. Meibom, B. Albrecht-Küpper, N. Diedrichs, W. Hübsch, R. Kast, T. Krämer, U. Krenz, H. G. Lerchen, J. Mittendorf, P. G. Nell, F. Süssmeier, A. Vakalopoulos, K. Zimmermann, *ChemMedChem* 2017, 12, 728–737.
- [9] E. A. Vecchio, J. A. Baltos, A. T. N. Nguyen, A. Christopoulos, P. J. White, L. T. May, *Br J Pharmacol* 2018, 175, 4036–4046.
- [10] C. K. Goth, U. E. Petäjä-Repo, M. M. Rosenkilde, *ACS Pharmacol Transl Sci* 2020, 3, 237–245.
- [11] D. Wootten, A. Christopoulos, P. M. Sexton, *Nat Rev Drug Discov* 2013, 12, 630–644.
- [12] K. A. Jacobson, *Biochem Pharmacol* 2015, 98, 541–555.
- [13] A. S. Hauser, M. M. Attwood, M. Rask-Andersen, H. B. Schiöth, D. E. Gloriam, *Nat Rev Drug Discov* 2017, 16, 829–842.
- [14] D. Weichert, P. Gmeiner, *ACS Chem Biol* 2015, 10, 1376–1386.
- [15] X. Yang, L. H. Heitman, A. P. IJzerman, D. van der Es, *Purinergic Signal* 2021, 17, 85–108.
- [16] X. Yang, M. A. Dilweg, D. Osemwengie, L. Burggraaff, D. van der Es, L. H. Heitman, A. P. IJzerman, *Biochem Pharmacol* 2020, 180, 114144.
- [17] M. Jörg, P. J. Scammells, *ChemMedChem* 2016, 11, 1488–1498.
- [18] A. Glukhova, D. M. Thal, A. T. Nguyen, E. A. Vecchio, M. Jörg, P. J. Scammells, L. T. May, P. M. Sexton, A. Christopoulos, *Cell* 2017, 168, 867–877.e13.
- [19] E. Kozma, P. S. Jayasekara, L. Squarcialupi, S. Paoletta, S. Moro, S. Federico, G. Spalluto, K. A. Jacobson, *Bioorg Med Chem Lett* 2013, 23, 26–36.
- [20] P. S. Jayasekara, K. Phan, D. K. Tosh, T. S. Kumar, S. M. Moss, G. Zhang, J. J. Barchi, Z. G. Gao, K. A. Jacobson, *Purinergic Signal* 2013, 9, 183–198.
- [21] M. I. Bahamonde, J. Taura, S. Paoletta, A. A. Gakh, S. Chakraborty, J. Hernando, V. Fernández-Dueñas, K. A. Jacobson, P. Gorostiza, F. Ciruela, *Bioconjug Chem* 2014, 25, 1847–1854.
- [22] J. Taura, E. G. Nolen, G. Cabré, J. Hernando, L. Squarcialupi, M. López-Cano, K. A. Jacobson, V. Fernández-Dueñas, F. Ciruela, *Journal of Controlled Release* 2018, 283, 135–142.
- [23] D. Greenbaum, K. F. Medzhradszky, A. Burlingame, M. Bogoy, *Chem Biol* 2000, 7, 569–581.
- [24] Y. Liu, M. P. Patricelli, B. F. Cravatt, *Proceedings of the National Academy of Sciences* 1999, 96, 14694–14699.
- [25] H. S. Overkleeft, B. I. Florea, *Activity-Based Proteomics: Methods and Protocols*, 2017.
- [26] K. J. Gregory, R. Velagaleti, D. M. Thal, R. M. Brady, A. Christopoulos, P. J. Conn, D. J. Lapinsky, *ACS Chem Biol* 2016, 11, 1870–1879.
- [27] V. Garcia, A. Gilani, B. Shkolnik, V. Pandey, F. F. Zhang, R. Dakarapu, S. K. Gandham, N. R. Reddy, J. P. Graves, A. Gruzdev, D. C. Zeldin, J. H. Capdevila, J. R. Falck, M. L. Schwartzman, *Circ Res* 2017, 120, 1776–1788.
- [28] M. Soethoudt, S. C. Stolze, M. V. Westphal, L. Van Stralen, A. Martella, E. J. Van Rooden, W. Guba, Z. V. Varga, H. Deng, S. I. Van Kasteren, U. Grether, A. P. IJzerman, P. Pacher, E. M. Carreira, H. S. Overkleeft, A. Ioan-Facsinay, L. H. Heitman, M. van der Stelt, *J Am Chem Soc* 2018, 140, 6067–6075.
- [29] X. Yang, T. J. M. Michiels, C. de Jong, M. Soethoudt, N. Dekker, E. Gordon, M. van der Stelt, L. H. Heitman, D. van der Es, A. P. IJzerman, *J Med Chem* 2018, 61, 7892–7901.
- [30] S. D. Hellyer, S. Aggarwal, A. N. Y. Chen, K. Leach, D. J. Lapinsky, K. J. Gregory, *ACS Chem Neurosci* 2020, 11, 1597–1609.
- [31] P. N. H. Trinh, D. J. W. Chong, K. Leach, S. J. Hill, J. D. A. Tyndall, L. T. May, A. J. Vernall, K. J. Gregory, *J Med Chem* 2021, 64, 8161–8178.
- [32] A. O. Helbig, A. J. R. Heck, M. Slijper, *J Proteomics* 2010, 73, 868–878.
- [33] D. M. Rosenbaum, S. G. F. Rasmussen, B. K. Koblika, *Nature* 2009, 459, 356–363.
- [34] B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden, C. E. Müller, *Pharmacol Rev* 2011, 63, 1–34.
- [35] E. A. Vecchio, J. A. Baltos, A. T. N. Nguyen, A. Christopoulos, P. J. White, L. T. May, *Br J Pharmacol* 2018, 175, 4036–4046.
- [36] C. K. Goth, U. E. Petäjä-Repo, M. M. Rosenkilde, *ACS Pharmacol Transl Sci* 2020, 3, 237–245.
- [37] O. Vit, J. Petrak, *J Proteomics* 2017, 153, 8–20.
- [38] A. O. Helbig, A. J. R. Heck, M. Slijper, *J Proteomics* 2010, 73, 868–878.
- [39] D. M. Rosenbaum, S. G. F. Rasmussen, B. K. Koblika, *Nature* 2009, 459, 356–363.
- [40] K. B. Rostovtsev, V. V., Green, L. G., Fokin, V. V. and Sharpless, *Angew. Chem. Int. Ed.* 2002, 41, 2596–2599.
- [41] E. M. Sletten, C. R. Bertozzi, *Acc Chem Res* 2011, 44, 666–676.
- [42] M. W. Beukers, L. C. W. Chang, J. K. von Frijtag Drabbe Künzel, T. Mulder-Krieger, R. F. Spanjers-King, J. Brussee, A. P. IJzerman, *J Med Chem* 2004, 47, 3707–3709.
- [43] D. Guo, T. Mulder-Krieger, A. P. IJzerman, L. H. Heitman, *Br J Pharmacol* 2012, 166, 1846–1859.
- [44] T. Amelia, J. P. D. van Veldhoven, M. Falsini, R. Liu, L. H. Heitman, G. J. P. van Westen, E. Segala, G. Verdon, R. K. Y. Cheng, R. M. Cooke, D. van der Es, A. P. IJzerman, *J Med Chem* 2021, 64, 3827–3842.
- [45] H. Nakata, *Journal of Biological Chemistry* 1990, 265, 671–677.

- [46] Z. Gao, A. S. Robeva, J. Linden, *Biochemical Journal* 1999, 338, 729–736.
- [47] C. Blex, S. Michaelis, A. K. Schrey, J. Furkert, J. Eichhorst, K. Bartho, F. Gyapon Quast, A. Marais, M. Hakelberg, U. Gruber, S. Niquet, O. Popp, F. Kroll, M. Sefkow, R. Schüle, M. Dreger, H. Köster, *ChemBioChem* 2017, 18, 1639–1649.
- [48] N. Sobotzki, M. A. Schafroth, A. Rudnicka, A. Koetemann, F. Marty, S. Goetze, Y. Yamauchi, E. M. Carreira, B. Wollscheid, *Nat Commun* 2018, 9, 1519.
- [49] F. M. Müskens, R. J. Ward, D. Herkt, H. van de Langemheen, A. B. Tobin, R. M. J. Liskamp, G. Milligan, *Mol Pharmacol* 2019, 95, 196–209.
- [50] R. Miyajima, K. Sakai, Y. Otani, T. Wadatsu, Y. Sakata, Y. Nishikawa, M. Tanaka, Y. Yamashita, M. Hayashi, K. Kondo, T. Hayashi, *ACS Chem Biol* 2020, 15, 2364–2373.
- [51] M. Ma, S. Guo, X. Lin, S. Li, Y. Wu, Y. Zeng, Y. Hu, S. Zhao, F. Xu, X. Xie, W. Shui, *ACS Chem Biol* 2020, 15, 3275–3284.
- [52] H. Muranaka, T. Momose, C. Handa, T. Ozawa, *ACS Med Chem Lett* 2017, 8, 660–665.
- [53] A. J. Kooistra, S. Mordalski, G. Pándy-Szekeres, M. Esguerra, A. Mamyrbekov, C. Munk, G. M. Keserü, D. E. Gloriam, *Nucleic Acids Res* 2021, 49, D335–D343.
- [54] P. J. F. Henderson, H. A. Lardy, *Journal of Biological Chemistry* 1970, 245, 1319–1326.
- [55] M. Klingenberg, *Biochim Biophys Acta Biomembr* 2008, 1778, 1978–2021.
- [56] E. C. Klaasse, A. P. IJzerman, W. J. de Grip, M. W. Beukers, *Purinergic Signal* 2008, 4, 21–37.
- [57] C. Allan, J. M. Burel, J. Moore, C. Blackburn, M. Linkert, S. Loynton, D. MacDonald, W. J. Moore, C. Neves, A. Patterson, M. Porter, A. Tarkowska, B. Loranger, J. Avondo, I. Lagerstedt, L. Lianas, S. Leo, K. Hands, R. T. Hay, A. Patwardhan, C. Best, G. J. Kleywegt, G. Zanetti, J. R. Swedlow, *Nat Methods* 2012, 9, 245–253.
- [58] H.-X. Liang, L. Belardinelli, M. J. Ozeck, J. C. Shryock, *Br J Pharmacol* 2002, 135, 1457–1466.
- [59] Schrödinger LLC, *Schrödinger Release 2019-1: Maestro*, New York, 2019.
- [60] K. Zhu, K. W. Borrelli, J. R. Greenwood, T. Day, R. Abel, R. S. Farid, E. Harder, *Journal of Chemical Information and Modeling* 2014, 54, 1932–1940.
- [61] P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, D. C. Klenk, *Analytical Biochemistry* 1985, 150, 76–85.
- [62] M. Rodbell, *J Biol Chem* 1964, 239, 375–380.
- [63] D. W. McKeel, L. Jarett, *Journal of Cell Biology* 1970, 44, 417–432.
- [64] A. Green, G. Milligan, S. B. Dobias, *Journal of Biological Chemistry* 1992, 267, 3223–3229.
- [65] Y.-C. Cheng, W. H. Prusoff, *Biochemical Pharmacology* 1973, 22, 3099–3108.
- [66] A. Kourounakis, C. Visser, M. de Groote, A. P. IJzerman, *Biochemical Pharmacology* 2001, 61, 137–144.
- [67] E. J. van Rooden, B. I. Florea, H. Deng, M. P. Baggelaar, A. C. M. van Esbroeck, J. Zhou, H. S. Overkleeft, M. van der Stelt, *Nature Protocols* 2018, 13, 752–767.
- [68] D. Wessel, U. I. Flügge, *Analytical Biochemistry* 1984, 138, 141–143.
- [69] J. Rappsilber, M. Mann, Y. Ishihama, *Nature Protocols* 2007, 2, 1896–1906.
- [70] J. Cox, M. Mann, *Nature Biotechnology* 2008, 26, 1367–1372.
- [71] F. J. van Dalen, T. Bakkum, T. van Leeuwen, M. Groenewold, E. Deu, A. J. Koster, S. I. van Kasteren, M. Verdoes, *Frontiers in Chemistry* 2021, 8, 1–13.

